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Parkinson’s disease is a neurodegenerative disorder that results in the 
degenerationof dopaminergic neuronsin the substantia nigra (SNc) of the 
midbrain. Understanding the molecular mechanisms underlying the cause of 
Parkinson’s disease (PD) has attracted the attention of manyresearchers in the 
last few decades. In spite of the recent technical advances in the field of 
neuroscience, the complete pathophysiology of PD is not fully understood. 
Examination of post-mortem brains from clinical PD cases has revealed 
precise mechanisms of the cell death cascade. These key processes have been 
replicated in experimental models of PD for a better understanding of the 
underlying molecular mechanisms. The discovery of 1-methyl-4-phenyl-1, 2, 
3, 6-tetrahydropyridine (MPTP) was another big leap in the field of PD 
research. MPTP has the ability to selectively destroy the dopaminergic 
neurons in the substantia nigra, hence serve as an excellent experimental 
model for PD. MPTP induced animal model has been shown to replicate most 
of the characteristic features of clinical PD cases. Hence, the first aim of the 
present study was to generate an acute MPTP-induced mouse model of PD. In 
order to validate the animal model, the expressions of various genes that are 
involved in the pathology of PD were examined. Tyrosine hydroxylase 
(TH)and dopamine transporter (DAT) are two major rate limiting enzymes in 
the dopamine synthesis. Gene expression analysis and Western blot analysis 
from the SNc of the MPTP-induced mouse model revealed that the expression 
pattern of TH and DAT significantly reduced at different time points. Since 
proinflammatory genes have long been implicated in PD pathogenesis, the 
expression pattern of TNFα and iNOS in the SNc of the MPTP-induced mouse 
model was analysed. It was observed that there was an increase in the levels of 
XXI 
 
TNF and iNOS during the first few days post injection However, this increase 
gradually decreased as the degeneration progressed. These results show that 
MPTP-induced gene expression changes are similar to those found in clinical 
PD cases. 
 There have been great strides in our knowledge about sphingolipids 
and the mechanisms by which they regulate numerous cellular processes. 
Dysregulated sphingolipid metabolism has been shown to underlie the 
pathophysisology of many neurodegenerative disorders. However, the role of 
these sphingolipids in the pathophysiology of PD is still not known. 
Sphingosine kinases are the major rate limiting enzymes in the sphingolpid 
metabolic pathway which produces the enigmatic sphingosine-1-
phosphate(S1P) that controls diverse physiological processes in the brain. The 
present study focuses on the role of one of the two sphingosine kinases, Sphk2 
and its metabolite S1P’s signalling in PD. Gene expression study and protein 
analysis revealed that the expression pattern of Sphk2 decreased significantly 
in the SNc of the MPTP-induced mouse model of Parkinson’s disease.  
Localization studies showed that Sphk2 was predominantly present in the 
mitochondria proposing for its potential role in mitochondrial functions. Since 
mitochondrial dysfunction has been reported to be the major pathological 
event in Parkinson’s disease, the present study focused on the role of Sphk2 
andits metabolite S1P in mitochondrial functions with special focus on PGC-
1α and itsdownstream targets. Consistent with previous data on the ability of 
S1P to activate p-CREB, our results showed that S1P can activate P-CREB in 
the MPP+-treated MN9D cells.  The localization of Sphk2 in the mitochondria 
and the ability of S1P to activate p-CREB led to the hypothesis that 
XXII 
 
Sphk2/S1P signalling axis might be involved in controlling PGC-1α and its 
downstream targets, as PGC-1α has a binding site for p-CREB. Supporting 
this hypothesis, functional studies using siRNA targeting Sphk2 in the MN9D 
cells revealed that the down regulation of Sphk2 alters the expression of the 
genes PGC-1α and NRF-1 that regulate mitochondrial functions.  There was 
also considerable decrease in TFAM (which is the gene involved in 
mitochondrial biogenesis) in the Sphk2 knock down group. In addition, lossof 
function of Sphk2 also significantly decreased the levels of intra cellular S1P. 
These results were comparable with the results obtained from the SNc of the 
MPTP induced mouse model and in the MPP+- treated MN9D cell. In 
addition, knock down of Sphk2 also lead to a significant decrease in the 
expression pattern of the antioxidant gene SOD2 with a concomitant increase 
in the ROS level. The present data showed that addition of exogenous S1P 
significantly reduces the ROS concentrationin MN9D cells treated with MPP+ 
andincreases the viability of a significant group of cells.The level of total 
cellular ATP was significantly lower in the Sphk2 knock down group and in 
theMPP+-treated groups. However, the levels of total cellular ATP was 
unaffected in the MPP+ treated groups in the presence of exogenous S1P. 
Furthermore, the cell death was minimal in the MPP+-treated groups in the 
presence of exogenous S1P. These results vouch for the protective role of 
Sphk2/S1P signalling in the neurons. The present study also reveals that S1P 
exerted its prosurvival effects by one of its receptors. Gene expression analysis 
from the SNc revealed that the mRNA expression of S1P1 receptor 
significantly decreased at different time points post-
MPTPtreatment.Immunoflourescence studies showed that the expression of 
XXIII 
 
S1P1 receptor was higher in the healthy neurons of the SNc. Blocking of the 
receptor using a commercially available receptor antagonist significantly 
reduced the viability of the cells. Moreover, the expression pattern of PGC-1α 
and NRF-1 was significantly reduced in the presence of a receptor antagonist. 
In addition, the expression of ROS was significantly higher when the receptor 
was blocked. Taken together, these results show that Sphk2/S1P has an 
important role to play in the survival of the dopaminergic neurons, thereby 
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ABC  avidin-biotin complex  
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1.1 Parkinson’s disease 
 Parkinson's disease is a debilitating condition of the brain characterized 
by gradual deterioration of motor functions due to the loss of dopaminergic 
neurons in the substantia nigra of the mid brain. The exact cause of this cell 
death is still not clear. The first comprehensible medical description about PD 
was written in 1817 by an English physician James Parkinson in his work 
entitled “An Essay on the Shaking Palsy”(Parkinson, 2002). However it was 
Jean-Martin Charcot and Alfred Vulpian who coined the name “Parkinson’s 
disease” by adding more symptoms to James Parkinson’s clinical 
description(Goetz, 2011). 
1.2 Epidemiology of PD 
 PD is the second most widespread neurodegenerative disorder after 
Alzheimer's disease. Nonetheless, appraisals of occurrence and predominance 
differ widely around studies; this is due to the differences in the 
methodologies used.  The occurrence of PD reported by studies representing 
all age gatherings ranged from 1.5 and 22 for every 100,000 man years. This 
rate, may be higher when recognizing just populations over the age of 60 
(Wirdefeldt et al., 2011). Approximately 1–2 % of the population over 65 
years suffer from PD. This estimate increases to 3 % to 5 % in people 85 years 
and older (Fahn, 2003). In some rare cases, PD-like symptoms has been 
observed in youngsters. Since PD is still regularly neglected as an analysis in 
more youthful patients; it is suspected that the amount of cases happening in 
people beneath the age of 40 may really be much higher than the assessed 10% 
of the population with the ailment(Golbe, 1991). Epidemiological studies have 
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also shown  that the occurrence and prevalence of PD are 1.5 to 2 times more 
in men than in women (Van Den Eeden et al., 2003). Future epidemiologic 
investigations of PD ought to be broad, incorporate definite quantifications, 
and gather data on natural exposures and hereditary polymorphisms 
1.3 PD - Signs and Symptoms 
 The substantia nigra of the midbrain contains thedopaminergic neurons 
which produce dopamine. Dopamine is a neurotransmitter responsible for 
coordinating movements. In Parkinson’s disease, there is a severe depletion in 
the levels of dopamine due to the degeneration of dopaminergic neurons. This 
results in the lack of control over body movements. The symptoms of PD have 
a gradual onset and usually develop simultaneously with the progression of the 
disease. The symptoms tend to worsen over time; if left untreated, it may lead 
to disability with associated immobility and falling. The early classic 
symptoms of PD include motor symptoms like postural instability, resting 
tremor, bradykinesia, and rigidity(Jankovic, 2008). The above symptoms are 
related to progressive loss of nigrostriatal dopamine and are usually corrected 
by treatment with Levadopa or dopamine agonists (Katzenschlager & Lees, 
2002). Nevertheless, as the disease progresses, symptoms that fail to respond 
to Levadopa develop (Pillon et al., 1989). These symptoms include flexed 
posture, freezing phenomenon, and loss of postural stability (Davie, 2008). 
Although the motor symptoms lead the clinical picture of PD, some patients 
are also associated with a range of non-motor symptoms like sleep, sensation, 
autonomic, moodditurbancesas well as cognitive disturbances like dementia 
(Shulman et al., 2001). These symptoms have a severe impact on the patient’s 
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quality of life(Wolters, 2009).  However, there is a considerable amount of 
heterogeneity among the individuals during the course of the disease.  
1.4 Diagnosis 
  Diagnosis of PD is a lot complicated, particularly during its early 
stages. Approximately 40% of the people with PD go undiagnosed and as 
many as 25% are diagnosed wrongly (Tolosa et al., 2006). This is due to the 
fact that as the disease progresses, the symptoms may imitate other disorders. 
Besides, currently there is no specific blood test or lab test available to 
diagnose the disease. Although functional imaging provides a way to 
discriminate typical from atypical PD; in most cases, physical examination of 
the patient forms the base for the diagnosis of PD. 
1.5 Existing treatments for PD 
 Although less effective in the advanced stage of the disease, 
medications are available to control the symptoms of PD. Amongst them, 
Levodopa continues to be the most effective treatment for PD (Katzenschlager 
& Lees, 2002). But this treatment is coupled with complications in motor 
activities such asdyskinesias, wearing off, and ‘on-off’ phenomenon (Lang & 
Lozano, 1998; Fahn et al., 2004). Another viable option at this stage is deep 
brain stimulation, although some patients meet the necessity for surgery. New 
medications that offer better control over the symptoms stay on developmental 
demand. However, both genes-as well as cell–based therapies have shown 
guarantee in early clinical studies (Correia et al., 2005). A key need yet to be 
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fulfilled is a treatment that stops or at least slows down the progression of the 
disease. 
1.6 Pathological hallmarks of PD 
 The archetypal pathological characteristic of PD involves the loss of 
the dopaminergic (DA) neurons. The DA neurons of the substantia nigra 
contains conspicuous amount of neuromelanin (Zucca et al., 2014). The loss 
of these neurons produces the depigmentation found in the substantia nigra 
(SNc) of PD patients. The depletion of DA  neurons  is most prominent in the 
dorsolateral  putamen  (Bernheimer et al., 1973). At the beginning of the 
symptoms, ∼80% of putamenal DA is degenerated, and ∼60% of SNc 
dopaminergic neurons has been lost. The pattern of SNc cell loss appears to be 
similar to the expression of the DA transporter (DAT) mRNA (Uhl et al., 
1994).  However, the DA neurons, which reside in the neighbouring ventral 
tegmental area (VTA), are least affected in PD (Uhl et al., 1985).  The other 
pathological characteristic that is classic of PD is the occurrence of 
intraneuronalproteinacious cytoplasmic inclusions, termed “Lewy Bodies” 
(LBs) which accumulates mainly in the cell bodies of surviving neurons (Gibb 
& Lees, 1988). These inclusions are termed Lewy neuritis when they are 
found in the neuronal processes. The LBs not only have conspicuous amount 
of aggregated α-synuclein, but also havecopious other proteins, which 
includesmembers of the ubiqiuitin–proteasome system and molecular 
chaperones, as well as lipids (Braak et al., 1999). The α-synuclein in the LBs 
is misfolded, post-translationally modified and ubiquitinylated. Theseinterfere 
with the mechanisms ofmicrotubule-based subcellular transport, thereby 
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causing synaptic dysfunction and other disruptions to neuronal homeostasis 
(Sheng & Cai, 2012).Several studies have shown that LBs are being constantly 
formed as the disease advances and they disappear when the neuron dies 
(Sheng & Cai, 2012). Lewy bodies thus offer a diagnostic markerand are 
extremely important for the pathological diagnosis. 
1.7 Potential risk factors in PD 
 The perspective of etiological factors in PD has changed amazingly 
from one of a simply sporadic premise to the view that both environmental 
and genetic factors help the onset of the disease. 
1.7.1 Aging- The cardinal factor 
 Age is one of the prominent risk factors in PD (Schapira & Jenner, 
2011; Reeve et al., 2014). Studies have shown that dopaminergic neuronal 
populations appear selectively susceptible to loss with aging compared to 
many other brain regions and those related to other neurodegenerative 
disorders (Hirsch et al., 1987).  In addition to this, studies have also shown 
that these dopaminergic neurons are particularly vulnerable to the 
mitochondrial dysfunction with advancing age (Bender et al., 2006; 
Kraytsberg et al., 2006). 
1.7.2 Environmental factors 
 Identifying environmental factors that persuade the progress of PD has 
proved undefined. A number of case-control studies have reported the likely 
contributions of exposures relating to a rural setting, including rural residence, 
making use of well water, farming, and exposure to pesticides in the 
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development of PD (Gorell et al., 1998). Nevertheless, the results were not 
consistent. The major drive for the environmental factors to be the major cause 
of PD came from the discovery of MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine). MPTP was first produced as a contaminant during illicit 
synthesis of a narcotic related to meperidine. This by-product caused 
strikingParkinsonism in four people after injectingit intravenously(Langston et 
al., 1984). MPTP has been shown to cross the blood brain barrier, wherein it is 
converted to the toxic 1-methyl-4-phenyl-2,3-dihydropyridium ion (MPP+) 
which has the ability to selectively kill dopaminergic neurons by inhibiting 
mitochondrial complex 1 (Nicklas et al., 1987; Przedborski et al., 2000). 
Inhibition of complex 1 kills the neurons due to mitochondrial energy deficits. 
Ever since the ability of MPTP (1-methyl-4-phenyl-1, 2, 3, 6-
tetrahydropyridine) to mimic few of the characteristics of PD wasdiscovered 
(Langston et al., 1983), persistent investigations has been conducted on 
identifying other environmental risk factors that could possibly be involved in 
the etiology of PD. Pesticides like rotenone and paraquat have also been  
shown to be implicated in the pathogenesis of PD. Studies have shown that 
exposure of animals to rotenone and paraquat causes pathological changes in 
the entire central nervous system similar to human PD (Abbott et al., 2001; 
Dinis-Oliveira et al., 2006; Pan-Montojo et al., 2010). In addition, 
occupational exposures to various metals have also proved to play a role in PD 
(Weisskopf et al., 2010). Exposure to organic solvents such as 
trichloroethylene (TCE), which is a common contaminant in ground water, has 
also been implicated in the development of PD (Koller et al., 1990). 
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1.7.3 Genetic factors in PD 
 Although PD was long considered to be sporadic in origin, monogenic 
Parkinsonism disorders are gaining increasing importance in recent years. 
Genetic factors appear to be the main cause in about 5-10% of the PD 
patients(Lesage & Brice, 2009). Nevertheless, degeneration of nigrostriatal 
DA neurons remain a general overlapping characteristic for both monogenic 
and sporadic Parkinsonism disorders (Hardy et al., 2003). Studies have shown 
that around 13 genetic loci are involved in the rare forms of PD (Farrer, 
2006).Out of the 13, around six PARK loci genes have been identified and 
have been reported to carry mutations that are related to relativeswho 
areaffected by PD. Out of the six genes, four have likewise been indicated to 
be implicated in sporadic PD(Farrer, 2006). 
1.7.3.1α-Synuclein(SNCA) 
 α-synuclein proteincontains 140-amino-acid and it belongs to a family 
of related synucleins that consist ofβ- and γ –synucleins (Clayton & George). 
The function of SNCA is still not clear; however, studies have shown that 
SNCA is vastly expressed in the mammalian brain, especially in the pre-
synaptic nerve terminals (Irizarry et al., 1996). Studies on mice with targeted 
SNCA deletion suggested a role for this gene in synaptic vesicle recycling and 
DA neurotransmission (Abeliovich et al., 2000). SNCA has been shown to 
play a crucial role in the pathophysiology of PD (Spillantini et al., 1998). The 
SNCA gene was the first to beknown to be involved in familial PD. This was 
first reported in Greek/Italian PD families with autosomal dominant pattern of 
inheritance (Polymeropoulos et al., 1997). SNCA mutations cause PD via a 
deleterious gain-of-function mechanism. Triplication of theSNCA geneleads 
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to an increase in the expression, thereby indicating that wild-type α-
synucleinwhen overexpressed is adequate tocause the disease. This condition 
was first reported in a large American family  (Farrer, 2006).  Moreover 
variations in the intronic regions and polymorphisms in the promoter region in 
SNCA have also been coupled with sporadic PD, indicating that proper 
maintainance of the transcriptional activity of the gene and mRNA stability 
may play a role in SNCA-associated PD (Mueller et al., 2005). Variability in 
the protein levels of SNCA might increase the susceptibility of the individual 
to PD (Pals et al., 2004). SNCA protein levels also accumulate with aging in 
the human substantia nigra.  The stabilization of SNCA with advancing 
age could be amajor factor in the pathogenesis of alpha-synucleinopathies(Li 
et al., 2004). 
1.7.3.2 Parkin 
 In an early onset of PDwith anautosomal recessive form of inheritance, 
a mutation was found at the PARK2 locus in Japanese families (Kitada et al., 
1998). The Parkin gene codesfor a 465-amino-acid protein and it functions as 
an E3 ubiquitin protein ligase (Shimura et al., 2000). Parkin mutations are 
quite common in familial PD. This gene has been shown to play a distinct role 
in the progress of early-onset PD (Scott et al., 2001). Around 50% of the early 
onset familial PD cases have recessive inheritance and about 10% of all early 
onset cases have been reported to contain mutations in the Parkin gene 
(Lucking et al., 2000). The rate of recurrence of Parkin mutations reducesas 
the disease progresses, and is extremely rare in patients with late-onset PD. 
Mutations in Parkin have also been reported in sporadic cases (Lucking et al., 
1998). Familial Parkin mutationsare due to loss-of-function and tend to affect 
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the interaction between Parkin and E2s or substrates whicheliminates Parkin’s 
E3 ligase activity. Parkin has been shown to provide resistance against the 
toxicity caused by α-synucleinoverexpression (Chung et al., 2004). 
Moreover,Parkin, when overexpressed in cultured cells, provides resistance 
against the stimuli that activates mitochondria-dependent apoptosis (Darios et 
al., 2003). In addition to this, Parkin is capable of curbing the toxic effects of 
α-synuclein by rescueing impaired proteasome function (Petrucelli et al., 
2002). This versatile capacity of Parkin has led researches to consider it  as a 
multipurpose neurprotectant(Feany & Pallanck, 2003). 
1.7.3.3 UCH-L1 
 Mutation in UCH-L1 was first discovered in a German family (Leroy 
et al., 1998a). UCH-L1 is an enzyme specific to neurons. Brain has a striking 
amount of UCH-L1, containing up to 1–2% of the entire soluble brain 
proteins(Leroy et al., 1998b). Genetic variability in the UCHL1 gene has been 
known to play animportant role in the progress of late-onset idiopathic PD 
(Maraganore et al., 2004). UCH-L1 functions as a dimerization-dependent 
ubiquitin protein ligase (Liu et al., 2002b). UCH-L1 regulates ubiquitin 
homeostasis in vivo by enhancing the stability of ubiquitin monomers (Osaka 
et al., 2003). In sporadic PD cases, UCH-L1 has been found to be localized in 
the LBs (Lowe et al., 1990). Mutation inUCH-L1 maydamage the total 
efficiency of the Ubiquitin Proteosome System. This might bedue to the 
decreased availability of free ubiquitin monomers, as a result leading to the 




 The gene coding for PTEN-induced putative kinase 1 (PINK1) was 
first identified in the PARK6 locus. It was initially discovered in three 
European families affected with PD (Valente et al., 2002). 
PINK1proteincomprises a total of 581-amino-acid that includes a 
mitochondrial targeting sequence at its N-terminus and a highly conserved 
protein kinase domain (Valente et al., 2004). Mutations in PINK1 were 
identified in the early onset of PD. Nevertheless, these mutations are rare in 
the late onset PD (Hatano et al., 2004). Physiological function of PINK1 is 
still under research. Mutation in PINK1 has been known to cause PD via a loss 
of function mechanism (Hatano et al., 2004). Some research has shown that 
PINK1 phosphorylates mitochondrial proteins which protects them against 
oxidative damage, thereby preventing mitochondrial dysfunctions(Pridgeon et 
al., 2007). This may have consequential implicative insinuations for sporadic 
forms of PD in which discrepancies in the functions of mitochondria have 
been proposed. 
1.7.3.5 DJ-1 
 Mutations in DJ-1 were first reported in both an Italian and a Dutch 
family to be linked to the PARK 7 locus (Bonifati et al., 2003). Nevertheless, 
these mutations are very rare in the early-onset cases (Lockhart et al., 2004). 
The DJ-1gene codes for a highly conservedprotein containing 189 amino 
acids. Brain has a profuse concentration of DJ-1 and is localized in the 
neurons and the glial cells (Bandopadhyay et al., 2004).  There is a noticeable 
change in the insoluble forms of DJ-1 in thepostmortem brains of sporadic PD 
patients (Moore et al., 2005). To date, no putative substrates for DJ-1 have 
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been identified. However, some researchers have suggested the promising role 
of DJ-1 as an antioxidant protein (Canet-Aviles et al., 2004). Knockdown of 
DJ-1 in cultured cells predisposes them to oxidative stress (Taira et al., 2004). 
Mutations in DJ-1 cause familial PD via a loss-of-function mechanism 
(Bonifati et al., 2003). Further illuminating the properties of these mutations 
may provide new understanding into the neuroprotective capacity of DJ-1. 
1.7.3.6 LRRK2 
 The gene leucine-rich repeat kinase 2 (LRRK2) was first identified in 
the PARK 8 locus (Paisan-Ruiz et al., 2004).Mutations in LRRK2 lead to 
autosomal dominant Parkinsonism which is found equally in sporadic and 
familial PD (Zimprich et al., 2004). Todate, around 50 different missense and 
nonsense mutations have been identified in LRRK2, of which 16 of them 
appear to be pathogenic (Nuytemans et al., 2010). The role of LRRK2 is still 
not clear, but the protein has been implicated in protein–protein interactions, 
regulation of neuronal survival and in the protection of neurites. The LRRK2 
gene is specifically noteworthy, as it has been uncovered to be the most 
important PD gene to be related particularly to the dopamine framework 
(Galter et al., 2006b). It is highly expressed in the striatum, which is the target 
zone of the nigrostriatal dopamine neurons, implicating that LRRK2 glitch in 
the striatum is especially important for PD (Galter et al., 2006a). 
1.7.3.7 ATP13A2 
 ATP13A2 gene consists of 29 exons and it codes for an1180-amino 
acid protein. Mutation in ATP13A2 causes autosomal recessive form of PD 
(Ramirez et al., 2006). Mutations in ATP13A2 generate truncated proteins that 
are very unstable. These proteins are usually present inside the endoplasmic 
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reticulum and are consequently degraded by the proteasome system. Several 
single heterozygous missense mutations in this gene have also been reported 
(Ramirez et al., 2006). However, the role of these mutations in PD 
pathogenesis is still under research. 
1.7.3.8 Genes likely to have a role in PD 
 Apart from the genes mentioned in the previous sections, there are a 
number of other genes which are known to be linked with PD. Some of these 
genes include GIGYF2 (Lautier et al., 2008), OMI/HTRA2 (Strauss et al., 
2005), PLA2G6 (Lu et al., 2012) and FBXO7 (Di Fonzo et al., 2009). In 
addition to these, risk factor genes like MAPT (Shulman et al., 2011), GBA 
(Lesage & Brice, 2009), NAT2 (Tan et al., 2000), INOS2A, GAK, HLA-
DRA, and APOE (Klein & Westenberger, 2012) have also been correlated 
with an augmented risk in the development of PD.  
1.8 Animal models of PD 
 Over the recent decades, researchers have mainly relied on rodents to 
model the features of PD. Among the many models, the commonly used ones 
are those which utilize toxins like 6-hydroxydopamine (6-OHDA), 1-methyl-
4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP), rotenone, or paraquat. These 
models are able to imitate the stages of PD. 
1.8.1 6-Hydroxy Dopamine (6-OHDA) model 
 6-OHDA has structural similarity with dopamine and noradrenaline 
(Breese & Traylor, 1971). Once administered ,this chemical is readily oxidised 
inside the neurons and produce highly toxic substances like hydrogen peroxide 
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and paraquinone (SANER & THOENEN, 1971). This toxin does not possess 
the ability to cross the blood brain barrier (BBB). However, direct cerebellar 
injection leads to selective loss of dopaminergic neurons in the SNc within 
few hours (Javoy et al., 1976; Jeon et al., 1995). This toxin mimics the early 
motor signs of PD. Nevertheless, it fails to produce extra-nigralpathology or 
Lewy body-like inclusions which are found in PD (Lane & Dunnett, 2008). 
1.8.2 Systemic rotenone model 
 This pesticide is a potent mitochondrial complex1 inhibitor which is 
used to generate the first chronic model of PD (Betarbet et al., 2000) . 
Rotenone is lipophilic and it readily crosses the BBB. However, this toxin has 
high variability in its action. It kills unrelated populations of neurons along 
with DA neurons which therefore limits its use (Fleming et al., 2004). 
1.8.2.1 Paraquat and Maneb 
 Paraquat (PQ) is a herbicide that crosses the BBB. It causes redox 
cycling and ROS formation. Inside the cells, PQ is transported into the 
mitochondria where it is reduced by the complex 1 thereby producing free 
radicals capable of damaging the mitochondria (Cochemé & Murphy, 2008). 
Administration of PQ causes significant loss of dopaminergic neurons in the 
SNc (Kuter et al., 2007). 
 Manganeseethylenebisadithiocarbamate (Maneb), is a fungicide which 
inhibits glutamate transport and affects the uptake and release of dopamine. 
Maneb is usually co-administered with paraquat (Vaccari et al., 1998). 
Paraquat/maneb when injected into rodents mimics different stages of clinical 
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PD cases. However, one disadvantage is that these toxins cause lung toxicity 
which is highly lethal (Cicchetti et al., 2005). 
1.8.3 MPTP model of PD 
 MPTP is the most commonly used toxin which when administered 
intoan animal mimics the hallmarks of PD. Inside the brain, this toxin is 
converted into its toxic metabolite MPP+ which is a potent complex 1 
inhibitor. MPTP is highly lipophilic and hence is readily transported through 
the BBB (Przedborski & Jackson-Lewis, 1997). MPTP has the ability to cause 
specific death of dopaminergic neurons in the substantia nigra. In mice MPTP 
exerts differential toxicity based on the strain used (Hamre et al., 1999).  
1.8.3.1Mechanismof MPTP action 
 MPTP is first metabolised by the enzyme MAO-B which is present in 
the endothelial cells lining the blood brain barrier (BBB) to 1-methyl-4-
phenyl-2, 3-dihydropyridium (MPDP+) which is then converted to 
MPP+(Sayre, 1989). This provides the first line of defence asMPP+ cannot 
enter the BBB. MPTP that is not converted to MPP+ in the periphery enters the 
brain, where they are taken up by the glial cells. Just like endothelial cells, 
glial cells also have a large amount of MAO-B which converts this MPTP to 
its toxic metabolite MPP+ (Ransom et al., 1987). The MPP+ thus produced 
activates various proinflammatory cytokines which in turn up-regulates 
inducible nitric oxide synthase (iNOS) which produces large amount of nitric 
oxide (NO). Neurons at the surrounding area of these glial-derived NO are at 
greater risk(Liberatore et al., 1999a). This MPP+ is further transported out of 
the glial cells by specific monoamine transporters. Once outside the glial cells, 
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these are readily taken into the dopaminergic neurons by the dopamine 
transporter (DAT) (Kitayama et al., 1992). DAT have a strong affinity towards 
MPP+.  Inside the neurons, MPP+ enters the mitochondria by diffusion through 
the mitochondrial inner membrane. MPP+impairs the mitochondrial 
respiration. This is due to the inhibition of complex I of the electron transport 
chain. This hinders the flow of electrons alongside the mitochondrial electron 
transport chain. Moreover, MPP+ can directly  inhibit complex III and IV of 
the electron transport chain (Mizuno et al., 1988).  Following the inhibition of 
mitochondrial complex 1 there is an excessive production of super oxides and 
free radicals in the neuronal cytosol (Cleeter et al., 1992), which leads to 
oxidative stress and cell death (Przedborski, 1992).  The type of cell death that 
occurs in the MPTP-induced animal model depends on the dosage and pattern 
of MPTP administration. Low or moderate dosages directed over an extended 
period of time incite an apoptotic type of cell death while high dosage in a 
short interval lead to an undeniably necrotic type of cell death (Jackson-Lewis 
et al., 1995). Hence, the dosage and time schedule used in generating the 
animal model affects the hallmarks of PD produced (Bezard et al., 1997). 
Moreover, the gender, age, sex and body weight of the mice are major factors 
that influence the sensitivity of the drug and the lesion produced (Sedelis et 
al., 2000). The present study makes use of the acute MPTP-induced PD mouse 
model based on the finding of Jackson-Lewis and Przedborski, (2007). This 
model involves four i.p. injections in a day ranging from 14 mg/kg to 20 




1.9 Possible Pathways involved in the pathogenesis of PD 
 Before the discovery of genes causing monogenic types of PD, several 
intriguing speculations have shown that different molecular pathways are 
involved in the propagation of PD pathogenesis. Accumulating evidences have 
confirmed that mitochondrial dysfunction, impairment of theubiquitin 
proteosome system (UPS) andoxidative stress may perhaps represent the 
prime molecular pathways that generally lie beneath the pathogenesis of both 
sporadic and familial forms of PD. In addition to this, inflammation andloss of 
neurotrophic factors have also been shown to play a major role in the progress 
of PD. 
1.9.1 Inflammation 
 The steady findings acquired by different animal models of PD suggest 
that neuroinflammation is an essential patron to the pathogenesis of PD and 
may further impel the progressive loss of nigral dopaminergic neurons.  
Although not the primary cause of PD, exaggerated inflammatory responses 
caused by glial reactions (Wu et al., 2002), T cell infiltration (Miklossy et al., 
2006), and increased expression of inflammatory cytokines are presently 
recognized as major characteristics of PD. Increased levels of pro-
inflammatory cytokines such as tumour necrosis factor-a (TNFα), interleukin-
1β (IL1β), IL6, inducible nitric oxide synthase (i NOS) and cyclooxygenase 2 
have been found in the substantia nigra of PD patients (Nagatsu et al., 2000; 
Tansey et al., 2007). This might be due to the activation of microglia in that 
region. Research has shown that inflammatory mediators like (IL1β) promote 
the aggregation of α-synuclein (Griffin et al., 2006). In addition to this, 
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activated macrophages have been shown to increase the nitrosylation of α-
synuclein in the neuronal cells (Shavali et al., 2006). 
1.9.2 Excitotoxicity 
 Inspite of the specific ultrastructural ﬁndings connected with dynamic 
excitotoxicdegeneration; there are no speciﬁc pathological characteristics of 
excitotoxicity. However, there is a decline in the glutamate receptor in the PD 
brain (Difazio et al., 1992), thus proposing that neurons expressing these 
receptors are susceptible to neurodegeneration. Moreover, neurotoxins such as 
MPTP, 6-hydroxydopamine and methamphetamine used to model PD exert 
their toxic effects through the stimulation of excitotoxic glutamate receptors 
(Olney et al., 1990). Increased calcium inﬂux also plays a crucial role in 
excitotoxicity in PD (Eimerl & Schramm, 1995; Surmeier et al., 2011). 
1.9.3 Impairment of the Ubiquitin-Proteasome System (UPS) 
 Rising proofpropose that impairment of the ubiquitin-proteasome 
system may additionally be involved in the pathogenesis of familial and 
sporadic types of PD (Giasson & Lee, 2003). In accordance with this idea, 
there have been structural and functional dearth in the 20/26S proteasome in 
the substantia nigra of sporadic PD patients (St. P. McNaught et al., 2003). 
The accumulation of cytotoxic proteins such as α-synuclein, inLewy bodies 
(Lbs) in DA neurons in sporadic PD emphatically suggests protein misfolding 
and consequent proteolytic stress, which perhaps imply impaired UPS function 
(Bence et al., 2001; Chung et al., 2001). α-synuclein functions by inhibiting 
the 20/26S proteasome thereby causing UPS dysfunction. (Snyder et al. 2003). 
Moreover, mutations in the Parkin gene have also been shown to cause 
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impairment in UPS pathway with ensuing proteolytic stress owing to abnormal 
protein aggregation, which mightresult in the inevitable death of DA neurons 
(von Coelln et al., 2004). 
1.9.4 Oxidative stress in PD 
 Oxidative stress is an alternate possibly vital pathway that could be 
involved in the development of PD-like pathology in the neurons. Numerous 
evidence from post-mortem studies revealed the involvement of oxidative 
stress in PD pathogenesis (Jenner, 2003). Oxidative stress may quicken as the 
disease progresses, and it is involved in a segment of the pathogenesis 
underlying the progression of PD. Mitochondria are the source of ROS 
production (Murphy, 2009). Defects in complex 1 of the respiratory chain has 
been known to cause the death of dopaminergic neurons through decreased 
synthesis of ATP and increased production of ROS,thereby leading to 
oxidative DNA damage consequently setting off an endless loop between 
mitochondrial dysfunction and oxidative stress (Orhan et al., 2004). In 
addition to this, levels of both free and bound nitrotyrosine, a steady indicator 
of the association of Reactive nitrogen species (RNS), have been shown to be 
increased in the affected zones of the MPTP mouse model of PD (Pennathur et 
al., 1999). Among the ROS-scavenging enzymes, superoxide dismutase 
(SOD) is frequently viewed as the first line of resistance against a ROS rise. In 
the post-mortem PD brains, an increase in the mitochondrial isoform of SOD2 
was observed. The latter observation is quite interesting since SOD2 is highly 
inducible in response to an excess of ROS (Saggu et al., 1989). In addition, 
some reports have singled out dopamine as potentially being the primary 
culprit in the death of dopaminergic neurons. Dopamine is an extremely 
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reactive molecule inclined to easy oxidation. On being oxidized, it can react 
with several cellular components producing increased amount of ROS (Meiser 
et al., 2013) . 
1.9.5 Mitochondrial dysfunction in PD 
 Mitochondria play a cardinal role in the apoptotic pathway(Desagher 
& Martinou, 2000). Opening of the mitochondrial permeability transition 
pores occur under conditions of oxidative stress leadingtothe 
failureofthemitochondrial membrane potential. Mitochondrial dysfunction 
mayconsequentlyretune the threshold for the activation of apoptotic pathways. 
An excess in apoptosis has been shown to participate in unwarranted acute or 
chronic cell loss in neurodegenerative diseases. Mitochondrial dysfunction 
plays a key role in the pathogenesis of PD. Substantial evidence has shown 
that sporadic and familial variants of PD have common pathways that unite at 
the mitochondria (Burbulla et al., 2010). The link between mitochondrial 
dysfunction and Parkinson’s disease became evident with the discovery of 
MPTP in the early 1980’s. MPTP has been shown to inhibit complex 1 
activity thereby causing the death of DA neurons (Dauer & Przedborski, 
2003).  Several epidemiological studies have proposed that MPTP and other 
complex 1 inhibitors like the pesticides rotenone and paraquat are implicated 
in sporadic PD (Sherer et al., 2002). When administered MPTP and paraquat 
cause aggregation of α-synuclein in the non-human primates and in mice 
(Forno et al., 1988; Manning-Bog et al., 2002; McCormack et al., 2002). In 
accordance with this data, some evidences have shown that mice that lackα-
synuclein are resistant to the effects of MPTP, while, transgenic mice 
overexpressingα-synuclein show increased susceptibility (Dauer et al., 2002; 
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Song et al., 2004). Such defects in complex 1 activity have been observed in 
the SNcat autopsy of several PD cases (Schapira, 1993). Mitochondrial 
dysfunction and complex 1 deficiency have been shown to impair striatal 
dopamine homeostasis due to depletion in the level of ATP,thereby leading to 
reduced vesicular uptake of dopamine and enhanced cytosolic dopamine 
metabolism (Choi et al., 2011; Sterky et al., 2012). Many pro-apoptotic 
mitochondrial proteins, for example, cytochrome c and apoptosis initiating 
factor (AIF), and their redistribution to the cytosol and nucleus throughout 
neuronal cell demise in vitro and in vivohave been extensively reported 
(Fiskum, 2000). Many factors are capable of triggering the release of pro-
apoptotic proteins from mitochondria, including elevated Ca2+, ROS, 
ceramides, and other cell death proteins (Camello-Almaraz, 2006). While 
much has been documented about the role of ROS, Ca2+ in PD, the role of 
sphingolipid metabolites like ceramides and sphingosine-1-phosphate in 
neurodegenerative diseases ( like PD) is still not known 
1.10 Lipids in the Central Nervous System (CNS) 
 Lipids are gaining increasing importance with respect to their roles in 
the CNS. Deregulated lipid metabolism has been reported in several CNS 
disorders and injuries. Lipid peroxidation leading to oxidative stress has been 
reported in neurodegenerative diseaseslike Alzheimer’s disease and 
Parkinson’s disease (Reed, 2011).  Lipids encompass a large number of 
chemically different molecules arising from combinations of fatty acids with 
different backbone structures. Mammalian cells contain more than 1000-2000 
lipid species. In general, lipids are classified into eight different categories. 
They areglycerolipids, glycerophospholipids, sphingolipids, fatty acyls, prenol 
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lipids, sterol lipids, saccharolipids, and polyketides (Fahy et al., 2009). In 
particular, great strides have been made in order to understand the mechanisms 
by which sphingolipids regulate numerous cellular processes in the CNS. 
1.10.1 Sphingolipids - The Enigmatic Class of Lipids 
 Sphingolipids consists of eighteen carbon amino-alcohol backbones 
which are synthesized in the ER from non-sphingolipid precursors. This vast 
family of lipids play important roles in membrane biology and offer many 
bioactive metabolites that regulate cell functions (Gault et al., 2010). These 
compounds have numerous roles, such as regulating signal transduction 
pathways, directing protein sorting, and mediating cell-to-cell interactions and 
recognition functions (Futerman & Hannun, 2004; Tani et al., 2007). 
Ceramides and sphingosine-1-phosphate are the two major sphingolipid 
metabolites which have diverse biological functions. 
1.10.2 Synthesis and metabolism of sphingolipids 
 De novo synthesis of sphingolipids begins at the cytoplasmic side of 
the endoplasmic reticulum (ER). It is instigated by the condensation of serine 
and palmitate to generate 3-keto-sphinganine catalyzed by serine 
palmitoyltransferase (Merrill, 2002). 3-keto-sphinganine is further reduced 
to sphinganine (dihydro-sphingosine, DHS) in two rapid enzymatic reactions 
by 3-keto-sphinganine reductase. DHS is then N-acylated 
by dihydroceramide synthase by means of various fatty acyl CoAs to 
form dihydroceramide (DHCer) which is then converted to Cer by a 
desaturase. Ceris latertranslocated from the ER to the Golgi apparatus in a 
non-vesicular transport approach by CERT (Hanada et al., 2003), a protein 
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which contains a phosphatidylinositol-4-phosphate-binding domain and a 
recognized catalytic domain which aids in lipid transfer. Cer and DHCer 
arelater used up bythe enzyme sphingomyelin synthase to form 
sphingomyelin(SM) and dihydrosphingomyelin (DH-SM) respectively (van 
Meer & Holthuis, 2000). Inside the Golgi lumen, GlcCers are further 
converted to lactosylceramides and glycosphingolipids (Spiegel & Milstien, 
2003). The other major metabolite sphingosine (Sph) is formed from Cer by 
ceramidase-catalyzed hydrolysis. Sph can also be produced during degradation 
of plasma membrane glycosphingolipids and SM in the endocytic recycling 
pathway.Sph and DHS are usually phosphorylated by SphKs to form S1P and 
dihydro-S1P, which are the substrates for S1P phosphatases which reside in 
the ER (Spiegel & Milstien, 2003). 
1.10.3 Sphingosine kinases 
 Sphingokinases (SphKs) are an evolutionarily conserved lipid kinase 
family that comprises five conserved domains (Liu et al., 2002a). Two 
mammalian isoforms of SphKs have been identified namely (SphK1 and 
SphK2), which vary in sequence, localization,catalytic properties and in their 
functions (Maceyka et al., 2005; Alemany et al., 2007). 
1.10.3.1 Sphingosine kinase 1(SphK1) 
 SphK1 (a 49-kDa protein) was initially purified from rat kidney. Based 
on tryptic peptides, murine SphK1 was later cloned (Kohama et al., 1998). In 
humans, the sphk1gene is located on chromosome 17 (17q25.2). Two 
isoforms, termed SphK1α and SphK1β (with 42.2 and 43.2 kDa predicted 
molecular weights) were identified. These two isoforms differed only in a few 
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amino acids at their N-terminal region. SphK1 has a broad tissue distribution, 
with elevated levels in the brain, heart, lungs and spleen. It has no trans-
membrane domains; however, it has three calcium/calmodulin-binding 
consensus sequences and a number ofprobable protein kinase phosphorylation 
sites (Kohama et al., 1998). SphK1 has a high specificity for the natural trans-
isomer of D-erythro-sphingosine.  
1.10.3.2Sphingosine kinase 2(SphK2) 
 On the basis of homology to SphK1, the second isoform termed 
SphK2, was cloned and characterized from mouse and human (Liu et al., 
2000).In human,Sphk2gene is on chromosome 19 (19q13.2). SphK2 is 
comprises around 240 amino acidsand numerous transmembrane domains are 
found at its N-terminus region which makes it longer than Sphk1 (Liu et al., 
2000). SphK2 shares around 80% sequence similarity with Sphk1 but have an 
added 200 amino acids, which makes it a predicted 68 kDa protein. However, 
SphK2 has reduced substrate specificity. Sphk2 has been shown to 
phosphorylate FTY720, which is an immunosuppressive drug presently in 
phase 3 clinical trials for kidney transplantation and multiple sclerosis 
treatment (Billich et al., 2003; Paugh et al., 2003; Sanchez et al., 2003). The 
localization of Sphk2 is actually cell type specific (Liu et al., 2000; Igarashi et 
al., 2003). 
1.10.4 Localization of Sphk1 and Sphk2 
 SphK1 is mainly cytosolic (Kohama et al., 1998). SphK1 is copiously 
expressed in the adult murine heart, spleen, lungs, and brain, while SphK2 is 
highly expressed in the brain, kidney, and liver (Liu et al., 2000). SphK2 has a 
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nuclear localization signal in its N terminal region. Mutation in the N-terminus 
region ofSphk2stopsit entering into the nucleus and therefore prevent it from 
inhibiting DNA synthesis (Igarashi et al., 2003). WhileSphK1 is 
predominantly localized in the cytosol in all cells, the localization of Sphk2 
depends on the type of cell. In HEK 293 cells, SphK2 has beenfound to be 
present in the plasma membrane, mitochondria, ER, Golgi, and in the cytosol 
(Hait et al., 2006), while, in COS7, MCF7,HeLa, and NIH 3T3 cells, it is  
predominantly localized in the nucleus (Okada et al., 2005; Sankala et al., 
2007). 
1.10.4.1 Synthesis of Sphingosine-1-phosphate 
 Sphingosine kinasesphosphorylate sphingosine to 
produceSphingosine-1-phosphate (S1P). S1P levels in cells are strongly 
regulated. S1P can also be dephosphorylated back to sphingosine by two 
specific S1P phosphatases. These phosphatases termed SPP1 ans SPP2fit in 
the family of magnesium-dependent, N-ethylmaleimide-insensitive type 2 lipid 
phosphate phosphohydrolaseswhichare presentin the Endoplasmic Reticulum 
(Le Stunff et al., 2002; Ogawa et al., 2003). In addition, S1P can as well be 
degraded by S1P lyase to hexadecenal and phosphoethanolamine (Takabe et 
al., 2008).  
1.10.4.2 Activation of Sphingosine kinases 
 SphK1 is largely present in the cytosol, and its substrate sphingosine 
(Sph), is produced in membranes .When it gets activated, Sphk1 translocates 
from the cytosol to the plasma membrane, resulting in theincreased release of 
S1P to the medium which, consecutively, triggers the autocrine/paracrine 
signalling(Shida et al., 2008). Translocation of Sphk1 to the plasma membrane 
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chairs it in the neighbourhood of its substrate sphingosine. Sphk1 interacts 
with phosphatidic acid that facilitates this translocation (Delon et al., 2004).A 
variety of growth factors have been shown to activate SphK1. These include 
platelet-derived growth factor (PDGF) (Hobson et al., 2001), vascular 
endothelial growth factor (VEGF) (Shu et al., 2002), hepatocyte growth 
factor(Duan et al., 2004), cytokines (TNF-alpha) (Xia et al., 2002; Pettus et 
al., 2003), GProteinCoupled Receptor ligands (acetylcholine) (van Koppen et 
al., 2001), and lysophosphatidicacid (Delon et al., 2004). Another research has 
shown that S1P itself is capable of activating Sphk1(Meyer zu Heringdorf et 
al., 2001). In addition to these, several other researchers have shown that the 
activation and the localization of Sphk1 is influenced by its interaction with 
several adaptor proteins like RPK118 (Hayashi et al., 2002), aminoacylase 
1(Maceyka et al., 2004), PECAM-1(Fukuda et al., 2004) and delta-
catenin/NPRAP (Fujita et al., 2004). However, the physiological importanceof 
these interactions is still not known. Unlike Sphk1, very little is known about 
Sphk2 interacting proteins. Latest reports have indicated thatSphK2can be 
stimulated byEGF, the protein kinase C activator (Hait et al., 2005, 2007). 
These compounds activate ERK1, whichinturn binds to SphK2. Binding of 
ERK1phosphorylates Sphk2at Ser351 and Thr578, escalating its enzymatic 
activity (Hait et al., 2007). Furthermore, reports have shownthatprotein kinase 
Dcatalyzes thephosphorylation of SphK2, therebyexportingit to the nucleus for 
ensuing cellular signaling (Ding et al., 2007). Neverthless, IgE receptor has 
been shown to cross-link on mast leading to the activation of both SphK1 and 
SphK2, which leads the translocation of both the sphingosine kinases to the 
plasma membrane (Olivera et al., 2006). Activation of bothSphK1 and SphK2 
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is vital for mast cell function (Olivera et al., 2007).Nevertheless, Bcl-xL, and 
IL-12 receptors have been shown to specifically interact with Sphk2. 
1.10.5 S1P Receptors 
 S1P was first identified as a ligand of endothelial differentiation gene 1 
(S1P1, EDGE1) receptor. Since then, the number of receptors which has high 
affinity for binding with S1P has increased to five. They are S1P1/EDG1, 
S1P2/EDG5, S1P3/EDG3, S1P4/EDG6, and S1P5/EDG8. S1P binds to one of 
these receptors thereby initiating various downstream processes such as 
cytoskeleton rearrangement, cell motility, invasion, angiogenesis, vascular 
maturation plus lymphocyte trafficking and function(Wang et al., 1999; 
English et al., 2000; Rosenfeldt et al., 2001; Graeler et al., 2002; Sugimoto et 
al., 2003; Pappu et al., 2007).S1P receptors are differentially expressed in all 
types of cells.  “Inside-out” signaling of S1P through these receptors are very 
crucial for many functions, like migration ofof fibroblasts towards PDGF 
(Hobson et al., 2001) and chemotaxis response of mast cells toward an antigen 
(Jolly et al., 2004). PDGF has been shown to induce translocation of SphK1 to 
the plasma membrane of the cells, which leads to the localized formation of 
S1P that stimulates S1P1 receptor which controls the movement of the cells 
towards the specific chemoattractant (Hobson et al., 2001; Rosenfeldt et al., 
2001). Incontrast, interaction between the same growth factorand S1P2 leads 
to opposing function by inhibiting cell movement (Goparaju et al., 2005). S1P 
can also act intracellularlywithout the aid of S1P receptors to promote cell 
proliferation and decrease apoptosis (Van Brocklyn et al., 1998; Rosenfeldt et 
al., 2001). Nonetheless, identification of intracellular targetsthat interact 
directly with S1P has been intangible.S1P1 is widely expressed. 
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S1P1knockout mice demonstrated impairment in angiogenesis and vascular 
maturation (Liu et al., 2000b). Furthermore, S1P1 has also been implicated in 
themaintainance of immune cell trafficking (Matloubian et al., 2004), 
endothelial barrier function (Singleton et al., 2005), and vascular tone (Sanna 
et al., 2006).  In addition to this, binding of S1P to this receptorresults in the 
activation of growth factor receptor tyrosine kinases (RTKs), through the 
following mechanisms 1) protein tyrosine kinases mediated phosphorylationof 
the RTK ; 2) enhanced production of growth factors; and 3) forming a 
signaling complex involving S1P1 and RTKs (signalplex). On the contrary, 
these growth factors can bind to the RTKs thus leading to the translocation 
and activation of SphK1 (Pitson et al., 2005), (Hobson et al., 2001).Moreover, 
some of these RTKs, like PDGF receptor, has the ability toaugment S1P1 
mRNA expression (Landeen et al., 2007), which leads to a complex 
interaction between RTKsand S1P receptors. 
1.10.5.1 Sphingosine kinases and S1P in the brain 
  The brain has profuse concentration of S1P when compared to the 
other organs (Edsall & Spiegel, 1999). During pathological conditions, the 
concentration of S1P further increases (Tosaka et al., 2001). There have been 
conflicting reports as to which one of thetwo Sphk isoformsmainly produces 
S1P in the brain. Although several reports have depicted Sphk1 to be the 
major isoform in the brain tissue, recent reports indicate that both the isoforms 
are substantially present in the CNS. This is evident from a report showing 
that neither of the Sphkknockdownmicedisplays anotable CNS phenotype. 
However, the double knock down of SphK1–SphK2 in mice showed a striking 
brain defect (Mizugishi et al., 2005; Meno-Tetang et al., 2006). FTY720 is a 
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potent S1P receptor agonist that is phosphorylated in vivo by Sphk2 (Meno-
Tetang et al., 2006). In experimental allergic encephalitis models, 
phosphorylated FTY720 restores nerve function by affecting the BBB and 
glial repair mechanism(Foster et al., 2007). FTY720 has also been shown to 
be a potential therapeutic drug for multiple sclerosis and is presently in phase 
3 clinical trials (Baumruker et al., 2007). S1P also plays an essential role in  
the motility of glioblastoma cells (Van Brocklyn et al., 2003). Current 
evidence has shown that sphingosine kinases have the ability to modulate the 
production of amyloid β precursor protein by the SH-SY5Y neuroblastoma 
cells. 
1.10.5.2 S1P receptors in the CNS 
 In spite of the CNS having the highest concentration of S1P receptors, 
not much is known about the function of S1P; S1P has been shown to promote 
the excitability of cultured DRG neurons which is mediated via S1P receptors. 
Blocking of these receptors abolished these effects (Zhang et al., 2006). 
Previous research has shown that NGF prompts the translocation of SphK1 to 
the plasma membrane which inturn leads to the activation of S1P1 resulting 
inRac activation and neurite extension (Toman et al., 2004). S1P2 knockout 
mice have been shown to exhibit occasional seizure activity (MacLennan et 
al., 2001). In addition, research has shown that S1P2 knockout mice are deaf 
and display a progressive loss of vestibular function (MacLennan et al., 2006; 
Kono et al., 2007). S1P has been shown to potentiate depolarisation-induced 
glutamate release in hippocampal neurons which was dependent on Sphk1 and 
S1P1 receptors, suggesting for its possible role in synaptic plasticity 
(Kajimoto et al., 2007). Moreover, S1P induces migration of transplanted 
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neural stem/progenitor cells to the injury site through its receptor S1P1 in 
spinal cord injury (Kimura et al., 2007). S1P plays a main role in the growth 
and survival of oligodendrocytes (Yu et al., 2004). The S1P receptor S1P5 is 
selectively expressed only in the oligodendrocytes. This receptor enhances the 
survival of mature oligodendrocytes by mediating the process retraction of the 
oligodendrocyte precursors and (Jaillard et al., 2005). In addition to this, the 
receptor S1P1 has also been shown to be involved in the proliferation of 
oligodendrocyte precursors. Hence, it seems likely that both S1P1 and S1P5 
function differently in the development of oligodendrocytes (Jung et al., 
2007). Astrocytes (the major type of glial cells in the CNS) have been shown 
to express S1P1, S1P2 and S1P3 receptors (Rao et al., 2003). S1P1receptor 
agonists have been shown to potentiate astrocyte migration. The receptors 
S1P1, S1P2, S1P3, and S1P5 were all been shown to be expressed by 
microglia. However, S1P3 expression in the microglia was lost after 2 weeks 
in culture (Tham et al., 2003).  
1.10.5.3 Role of Sphingosine kinases and S1P in neurodegeneration 
 Sphks and S1P play a major role in maintaining a delicate balance 
between neuronal survival and death. In recent years, the roles of Sphks/S1P 
in neurodegenerative disorders are gaining increasing importance. 
Disturbedsphingolipid metabolism has been reported in Alzheimer’s disease 
(AD) (He et al., 2010). A recent study has shown that SphK2 isup-regulated in 
the brains of Alzheimer's diseasepatients, via the modulation of BACE-1 
activity through its metabolite S1P (Takasugi et al., 2011). Furthermore, Aβ 
treatment of SH-SY5Y cells resulted in a strong inhibition of SphK1 activity 
coupled with an elevation of the ceramide/S1P biostat (Gomez-Brouchet et al., 
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2007). SPHK1/S1P1 signalling axis plays an essential role in the proliferation 
of astrocytes thus protecting hippocampal neurons from kainicacid-induced 
neurodegeneration(Lee et al., 2010). Sphk1/S1P receptor signalling has a 
control on the proliferation of glial cells in mice with Sandhoff disease(Wu et 
al., 2008). Another study has shown that deletion of Sphk2 leads to increase in 
lesion size and affects neurological function in an experimental stroke model 
(Pfeilschifter et al., 2011a).  While Sphk2 has always been considered as a 
“villainous gene” promoting cell death, the above study throws light on the 
protective effect of Sphk2/S1P signalling in the brain. Changes in sphingolipid 
metabolism have also been reported in other neurological disorders like HIV 
dementia, brain ischemia, hypoxia and inflammation (Haughey et al., 2008; 
Wei et al., 2011; Grin'kina et al., 2012). Recently, it was reported that 
inhibition of Sphk1 in the SH-SY5Y cells reduced the cell viability and 
concurrently increased the reactive oxygen species (ROS) level in an invitro 
model of PD (Pyszko & Strosznajder, 2014).  However, until now, the role of 
Sphk2/ S1P receptor signaling in Parkinson’s disease (PD) remains unknown. 
1.11 Aims of the present study 
1.11.1 To establish an acute MPTP-induced PD mouse model 
 In order to produce reproducible lesions with minimal death rate in the 
strain of animals used, an acute MPTP-induced PD mouse model with a total 
dosage of 72mg/kg was used in the present study. 
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1.11.2 To validate the animal model by investigating the degeneration of 
dopaminergic neurons in the substantia nigra. 
 MPTP have been well known to cause degeneration dopaminergic 
neurons in the substantia nigra. In order to study the pathological changes in 
the substantia nigra in our acute MPTP model, the following experiments were 
carried out.  
 In order to investigate the degeneration of dopaminergic neurons in the 
substantia nigra, the sections were stained with cresyl violet stain to visualize 
the Nissl granules. 
 Immunofluoresence staining with TH antibody was also done in order 
to study the loss of TH positive neurons 
 mRNA and protein expression pattern of TH in the substantia nigra at 
different days post MPTP treatment was analysed  
1.11.3 To establish an in vitro model of PD using MN9D cell line 
 MN9D is an immortalized embryonic mesencephalic neuronal cell 
line, which was established by somatic cell fusion by Choi et al., (1991).  
 In order to investigate the dopaminergic nature of these cells, they 
were stained with both TH and Neu-N antibodies. 
 The MN9D cells were treated with 200μM MPP+ in order to establish 
an invitro model of Parkinson’s disease. 
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1.11.4 To investigate whether the dopaminergic neurons of the substantia 
nigra expresses both Sphk1 and Sphk2 
 Coronal midbrain sections were stained with both Sphk1 and sphk2 
antibodies in order to investigate whether the dopaminergic neurons of the 
substantia nigra express sphingosine kinases. 
1.11.5 To study the localization of Sphk2 in the MN9D cells 
 The localization of Sphk2 has been shown to be cell type specific. In 
order to check if sphk2 was present in the mitochondria in the MN9D cells the 
following experiments were performed. 
 Western blot analysis was done with Sphk2 antibody using the 
mitochondrial and cytosolic fractions. 
 Mito-tracker dye was used before doing immnuofluorescence, in order 
to check if sphk2 staining co-localizes with the mito-tracker. 
1.11.6 To study the expression pattern of Sphk2 in the substantia nigra 
post MPTP treatment 
 Sphingosine kinases play a major role in many neurodegenerative 
disorders. However the role of Sphk2 in PD is still not known. The main aim 
of this part of my study was to examine the expression pattern of Sphk2 in the 
substantia nigra at different time points post MPTP treatment. 
 The sections were stained with Sphk2 antibody to compare the 




 Gene expression analysis and Western blot analysis of the expression 
pattern of Sphk2 after MPTP-treatment was done with the substantia nigra 
tissues. 
 The same set of experiments were carried out with the MN9D cells in vitro 
1.11.7To investigate the function of Sphk2/S1P signalling in promoting 
mitochondrial functions in Parkinson’s disease 
 Mitochondria have an importantrole to play in the regulation of cell 
death, which is a key feature of neurodegeneration. In recent years, PGC-1α 
and its down-stream targets have emerged as the key regulators of 
mitochondrial biogenesis and respiration. Various reports have shown that 
PGC-1α is down regulated in clinical PD cases.  S1P has been shown to 
activate the cAMP response element-binding protein (CREB) transcription 
factor through phosphorylation at Ser133 (Che et al, 2012).  Interestingly, 
previous studies have demonstrated that the PGC-1α gene possesses a binding 
site for CREB. The effects of S1P on CREB activation lead the present author 
to speculate that S1P might promote mitochondrial functions through 
activation of the PGC-1α pathway in the dopaminergic neurons.  Hence in the 
present study, the role of Sphk2/S1P signalling in promoting mitochondrial 
functions in the MPTP-induced mouse model of Parkinson’s disease and in the 
MPP+ treated MN9D cells was evaluated.  
 Functional studies were carried out in the differentiated MN9D cells 
using the siRNA-mediated knockdown approach, in order to study the effects 
of Sphk2 loss on the PGC-1α pathway.  
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 The MPP+-treated groups were S1P with exogenous S1P in order to 
study the protective effects of S1P on the MPP+-treated MN9D cells and to 
investigate the effects of S1P on the PGC-1α pathway in the MPP+-treated 
cells. 
 The expression pattern of PGC-1α, NRF-1, p-CREB were analysed in 
the different treatment groups by Western blot analysis. Further, the levels of 
total cellular ATP, ROS levels and SOD 2 were measured 
 Viability of the cells under various experimental conditions was also 
measured.  
1.11.8 To investigate whether S1P functions through one of its  receptors 
the following experiments were done 
 Gene expression analysis of all the receptors in the substantia nigra at 
different time points post MPTP-treatment was done 
 Specific receptor antagonist for S1P1 receptor, W123 was used to 
block the receptor in order to investigate whether S1P functions through S1P1 
receptor in the MPP+- treated cells. 
  Effects of S1P1 receptor antagonist on the expression pattern of PGC-
1α and NRF-1 were analyzed 
 Effect of a receptor antagonist on the expression pattern of ROS was 
analysed 















 To generate the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine 
(MPTP) - induced model of PD, adult male C57BL/6J mice that were aged 8-
10 weeks and weighed 20-25g were used. For the generation of MPTP-
induced PD models, these selected age, strain, gender, and weight of animals 
were the most favoured and considered reliable as described by Jackson-Lewis 
and Przedborski (2007). A total of 130 mice were used for the study. All the 
experiments were carried out in compliance with the approved guidelines of 
the Institutional Animal Care and Use Committee, National University of 
Singapore. Animal suffering and the number of animals used for the 
experiments were very carefully considered and minimized to a minimum.  
2.2 MPTP treatment 
2.2.1 Materials required 
 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP-
HCl)  (Sigma, USA)  
 0.9% NaCl 
2.2.2 Injections 
Jackson-Lewis and Przedborski (2007) have established the described protocol 
used in this study for the MPTP-induced PD model. The animals were 
acclimatized for five days in disposable cages with necessary food and water 
before the administration of MPTP. The dosage of the administered MPTP 
was reduced to 72 mg/kg from the original dosage in the protocol since the 
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original dosage caused acute death in the animals up to 80-90%. The reduced 
dosage used in the established model in the present study caused a relatively 
lower percentage of animal death at 20-30%. The administration of MPTP 
(Sigma, USA) dissolved in 0.9% sterile saline was performed. A total dosage 
of 72mg/kg was administered at 2 hour intervals in a series of four 
intraperitoneal injections [18mg/kg (free base) in 200μl saline each]. The same 
volume of saline was injected into the control animals. A fume hood and 
necessary PPE were used for all the injections to provide necessary safety and 
to prevent the personnel from MPTP exposure during the administration of 
MPTP. For a speedy recovery, the MPTP-injected animals were placed on 
heating pads for an hour. Till the animals were sacrificed, they were isolated.  
Later to the administration of MPTP, the MPTP-induced animals and time-
matched controls were sacrificed at days 1, day 3 and day 7. 
2.3 Isolation of brain samples 
2.3.1 Fresh brain samples for RNA isolation 
 Ketamine-medetomidine was used to anaesthetize the mice from days 
1, 3, 7 post MPTP injection and control animals. They were then decapitated. 
Using forceps, the brains of these animals were cautiously removed and 
cleansed, in order to wash off excess blood, with ice-cold 1X PBS. These 
brains were then snap-frozen in liquid nitrogen and were stored at -80ºC for 
future processing.  
2.3.2 Perfusion 
 Ketamine-medetomidine was used to anaesthetize the mice from days 
1, 3, 7 after the final MPTP injection and control animals. Perfusion using 4% 
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paraformaldehyde was performed on the animals in order to isolate the brains. 
2% paraformaldehyde was used for post fixing for 2 hours. The fixed brains 
were then transferred to 15% sucrose solution in PBS overnight. The 
following day, these brain samples were cryo-frozen using liquid nitrogen and 
were stored at a temperature of -80ºC until they were cryosectioned.  
2.4 Isolation of the substantianigra 
 The substantia nigra was isolated by mounting the brains onto cryo-
holders. The brains were trimmed to the midbrain using the mouse brain atlas 
coordinates. 300μm thick sections were sectioned which was followed by the 
removal of overlying cortex and hippocampus. In the region slightly above the 
pigmented substantia nigra, a horizontal cut was made. This facilitates the 
removal of the substantial nigra once a vertical cut it made perpendicular to it. 
The substantia nigra was then stored at a low temperature of -80ºC for further 
RNA or protein isolation that would be performed later.  
2.5 Cell culture 
2.5.1 Materials required 
 Phosphate buffered saline (PBS) (0.1M, pH 7.4) 
 Trypsin- EDTA (10X, Sigma, USA) 
 Dulbecco's Modified Eagle Medium (DMEM) (Gibco, USA)  
 Fetal bovine serum (FBS) (HycloneThermo scientific, USA) 




 Dr. Alfred Heller and Dr. Lisa Won from the University of Chicago 
provided the MN9D dopaminergic neuronal cell line and were cultured in 
DMEM (Gibco, USA) supplemented with 10% FBS (Hyclone, Thermo 
Scientific, USA). The cultures were maintained at a temperature of 37º C with 
5% CO2. Every two days, the medium was changed. The cell cultures were 
rinsed (after reaching a confluence of 70-80%) with warm 1XPBS after which 
they were trypsinized using Trypsin-EDTA-1X (Sigma, USA) in PBS.  
2.6 Cell differentiation 
2.6.1 Materials required 
 Sodium butyrate (NaBu) (Sigma, USA)  
 MPP iodide (Sigma, USA) 
 6-well and 96-well plates (Corning Costar, Sigma, USA)  
2.6.2 Procedure 
 As required by the needs of the experiment, the MN9D cells were 
either plated on a 96-well plate or were plated on a 6-well plate. For the 
differentiation of the cells (Choi et al), DMEM (Gibco, USA) which was 
supplemented with 10% FBS (HycloneThermo Scientific, USA) and 1mM 
sodium butyrate (Sigma, USA) was used. Every second day, the medium was 
changed and differentiation of the cells was allowed for a minimum of five 




2.7 Cell treatment Protocols 
2.7.1 Materials required 
 MPP+ (Sigma Aldrich, St. Louis, USA) 
 S1P    ( Sigma Aldrich, USA) 
 W123 (Cayman Chemicals) 
2.7.2 MPP+ treatment 
 In order to achieve a 10mM stock solution, measurement of the MPP 
iodide (Sigma, USA) serum-free DMEM (Gibco, USA) replaced the complete 
medium containing the differentiated cells, was done within a fume hood and 
it was dissolved in PBS-1X. Fresh MPP iodide solution was prepared 
separately for every experiment performed. The stock solution was diluted in 
serum-free DMEM (Gibco, USA), in order to acquire a concentration of 
200μM. The medium that contains the MPP+ was then added to the cells and 
was incubated with 5% CO2 for 24 hours at a temperature of 37ºC.  
2.7.3 Treatment with S1P and W123 
 In some experiments, 1μM of S1P and 15μM of W123 were added to 
the culture medium 1hr before MPP+treatment. 
2.8 RNA isolation 
2.8.1 RNA isolation from tissues 
2.8.1.1 Materials required 




 Nuclease free water 
 70% ethanol 
 Spectrophotometer (Nanodrop; Thermo Scientific, MA, USA) 
2.8.1.2 Procedure 
 Total RNA from the substantia nigra tissue was isolated using the 
RNeasy plus Universal Mini Kit following the manufacturer’s protocol. 900μl 
of lysis buffer was added to each tube containing the tissues and homogenized 
for 1 minute using a homogenizer. The tubes containing the homogenate were 
placed at room temperature for 5 minutes. Following this 100μl of gDNA 
eliminator solution was added to the tubes and the tubes were shaken 
vigourously for 15 sec. around 180μl of chloroform was added to the tubes 
and the tubes were again shaken vigorously for 15 sec. The tubes were then 
kept at room temperature for 2-3 mins. Following this, the tubes were 
centrifuged at12000g for a durationof 15 mins at 4oC. The upper aqueous 
phase was carefully taken out and added to new centrifuge tubes. Equalvolume 
of 70% ethanol was added to the tubes and was thoroughly mixed. The 
mixture was transferred to spin columns and was centrifuged at 10,000rpm at 
30 secs. Following this RW1 buffer and RPE buffer was added to the spin 
columns. After giving a brief dry spin, the RNA bound to the spin columns 





2.8.2 RNA isolation from cells 
2.8.2.1 Materials required 
 RNeasy mini kit (Cat. No. 74106, Qiagen, Germany) 
 70% ethanol 
 β-mercaptoethanol 
 Spectrophotometer (Nanodrop; Thermo Scientific, MA, USA) 
2.8.2.2 Procedure 
 The total RNA was isolated using QiagenRNeasy plus mini kits 
following the manufacturer’s protocol. Approximately 3X106 cells were 
collected from each sample for RNA isolation.  The media from the six well 
plates were removed and the cells were first washed with warm 1X PBS for 
two times. This was followed by the addition of 600μl of RLT lysis buffer 
supplemented withβ-mercaptoethanol was addedto each well of the 6-well 
plate. After ten minutes the cells were scrapped using a scrapper and the lysate 
was transferred carefully to a new centrifuge tube. Equal volume of 70% 
ethanol was added to the cell lysate. This mixture was further homogenised by 
using a syringe. After thorough mixing, the samples were transferred to the 
RN easy spin column and centrifuged at a speed 13,000rpm for 1 min at room 
temperature. After spinning, the flow through wasdiscarded and 700μl of RW1 
was added to the spin columns and centrifuged at 13,000rpm for 1 min at 
room temperature. The flow through was again discarded. This step was 
followed by the addition of 500μl of RPE twice and the columns were 
centrifuged at 13,000rpm for 1 min twice. Before eluting the RNS from the 
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spin columns, the columns were given a dry spin for duration of 2 mins in 
order to remove any excess buffer. The RNA attached to the spin column was 
carefully eluted in 30μl of nuclease-free water. The concentration of RNA 
after elution was measured using a spectrophotometer.  
2.9 cDNA synthesis 
2.9.1 Materials required 
 Superscript VILO cDNA synthesis kit (Invitrogen, USA)  
 RNAse-free water 
 RNA 
2.9.2 Procedure 
 With the use of 2μg of RNA, reverse transcription was carried out. 
To2μgof RNA, 4μl of 5X VILO reaction mix and 2μl of superscript enzyme 
mix were added. Along RNAse-free water, the reaction mixture was concocted 
up to 20μl. Incubation of the combination was done at a temperature of 25°C 
for duration of 10mins later to which transfer of the reaction was made to a 
temperature elevation of 42°C for duration of 60mins. Termination of the 
reaction occurs when it reaches a temperature of 85°C and after duration of 
5mins. The cDNA obtained was stored at a temperature of -20°C for further 
analysis. 
2.10 Real time RT-PCR 
2.10.1 Materials required 
 Fast SYBR green master mix (Applied Biosystems, USA)  
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 Primers (1st BASE, Singapore)  
 MicroAmp Fast optical 96-well reaction plate (Applied Biosystems, 
USA)  
2.10.2 Procedure 
 RT-PCR analysis was carried out in real time using the ABI 7900HT 
instrument (Applied Biosystems, USA) with the manufacturer recommended 
PCR settings for the reaction. Addition of around, 5μl of the Fast SYBR green 
master mix (Applied Biosystems, USA), 1μl of forward and reverse primers 
each and 3μl nuclease-free water were added to each of the wells of the 96-
well reaction plate. This was followed by the addition of 1μl of the cDNA 
(cDNA from the synthesis step diluted with nuclease-free water 1 in 10 ratio) 
before loading into the instrument for the analysis. For internal control, Mouse 
beta-actin primers were used, and 2^ΔΔCt method was used to calculate the 
fold change in expression.  
2.11 Protein extraction 
2.11.1 Extraction of total protein from the MN9D cells 
2.11.1.1 Materials required 
 Mammalian protein extraction reagent (Pierce, USA)  
 Protease inhibitor cocktail kit (Pierce, USA)  
 EDTA 
 Cell scrapper 
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 Centrifuge tubes 
2.11.1.2 Procedure 
 The culture medium was removed from the 6-well plates containing 
various treatment groups.  The cells were first washed with warm PBS for two 
times. Following which 200μl of mammalian protein extraction reagent 
(Pierce, USA) combined along with protease inhibitor and EDTA were added.  
The plates were kept in a shaker for 15 mins. The cells were then scrapped 
using a scrapper and the cell lysates were collected in a new centrifuge tube. 
The cell lysates were centrifuged at a speed of 13,000 rpm for 20 mins. The 
supernatant contained the protein. Following this the supernatant was carefully 
transferred to a new tube and was stored at -80ºC for further analysis. 
2.11.2 Extraction of total protein from the isolated tissues 
2.11.2.1 Materials required 
 Tissue protein extraction reagent (Pierce, USA)  
 Protease inhibitor cocktail kit (Pierce, USA)  
 EDTA 
 Homogenizer 
 Centrifuge tubes 
2.11.2.2 Procedure 
 Around 200μl of tissue protein extraction reagent combined with 
Protease inhibitor and EDTA were added to the tissues. The mixture was 
homogenized. The homogenate was transferred to new centrifuge tubes and 
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were centrifuged at 13,000 rpm for a duration of 20 mins. The supernatant 
contained the tissue protein. This was then carefully transferred to a new 
centrifuge tube and was stored at -80ºC for further analysis 
2.11.3 Extraction of mitochondrial and cytosolic protein 
 Materials required  
 Mitochondria Isolation Kit for cultured cells (Pierce, USA) 
 Protease inhibitor cocktail kit (Pierce, USA)  
2.11.4 Procedure 
 Before starting the protein extraction the buffers were thawed at room 
temperature. Protease inhibitor cocktail was added to the reagent amount 
being used according to the manufacturer’s instruction. The culture medium 
was removed from the six well plates following which the cells were washed 
with warm 1X PBS twice and were tryspsinised with 0.2X TE. The cell 
suspension was centrifuged at 850g for 2 mins in a micro centrifuge tube. The 
supernantant was carefully removed and discarded. To the cell pellet, 800μl of 
mitochondrial isolation reagent A was added. The mixture was then vortexed 
for 5 secs and was incubated on ice for 2 mins. To this 10μl of Mitochondrial 
isolation reagent B was added and vortexed for 5 secs. This was again 
incubated on ice for 5 mins and vortexed at maximum speed every 
minute.800μl of mitochondrial reagent c was added to this mixture and the 
tube was inverted several times to mix the reagents. This mixture was 
centrifuged at 700g for 10 mins at 4C. The supernatant was transferred to a 
new tube. In order to obtain more purified fraction of mitochondria with >50% 
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reduction in the lysosomal and peroxisomal contaminantscentrifugation was 
done at 3,000g for 15 mins. The supernatant containing the cytosolic fraction 
was carefully aspirated and transferred to anew tube. The pellet contained the 
mitochondria. 500μl of reagent C was added to this mitochondrial pellet and 
was centrifuged at 12,000g for 5 minutes. The supernatant was discarded. 
Around 100μl of 2 % CHAPS in TBS were added to the pellet containing the 
mitochondria. Following this the tubes werevortexed for 1 minute and 
centrifuged at maximum speed for 2 mins. The supernatant contained the 
mitochondrial protein which was quantified and used for Western blot 
analysis. 
2.11.5 Estimation of protein concentration 
2.11.5.1 Materials required 
 Protein assay dye (BioRad, USA)  
 Bovine serum albumin protein standard (BioRad, USA)  
2.11.5.2 Procedure 
 Through the use of Bradford method, protein sample concentration was 
estimated with bovine serum albumin (BSA) (BioRad, USA) as the standard. 
Addition of 10μl of the samples or standard to a 96- well plate was performed 
after the serial dilution of BSA ranging from 0 mg/ml to 1 mg/ml. Addition of 
200μl of the dye to each well was performed, prior to which, the protein assay 
dye was diluted in the ratio 1:5. For each of the sample or standard, the 
reactions were triplicated after which the incubation of the plate was done for 
a time period of 15mins. After incubation, the absorbance was measured at 
595nm using a precision microplate reader (Molecular devices). Plotting of a 
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standard graph was done by using absorbance values of the standard solutions, 
with which the estimation of the sample protein concentration was calculated 
2.11.6 Western Blotting 
2.11.6.1 Materials Required 
 Polyvinylidenedifluoride membrane (BioRad, USA)  
 10x Tris/Glycine/SDS (BioRad, USA)  
 Non-fat dry milk powder (BioRad, USA)  
 Pico chemiluminescent substrate Kit (Pierce, Thermo Scientific, USA)  
 10x Tris/Glycine buffer (BioRad, USA)  
 Mini transfer blot filter paper (BioRad, USA)  
 Stripping buffer (Pierce, Thermo Scientific, USA)  
 CL-Xposure film- clear blue film (Pierce, Thermo Scientific, USA)  
Equipment 
 Film developer (Konica Minolta, Singapore)  
 Gel-casting apparatus (BioRad, USA)  
 Densitometer with Quantity One software (BioRad, USA)  
 Electrophoresis Unit (BioRad, USA)  
 Semi dry transfer blot (BioRad, USA)  
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10% Resolving gel 
 1.5M Tris (pH 8.8)- 2.5 ml  
 10% sodium dodecyl sulphate (SDS)- 0.1 ml  
 30% acrylamide mix- 3.3 ml  
 10% ammonium persulphate- 0.1 ml  
 tetramethylethylenediamine (TEMED)- 0.004 ml 
 Water- 4 ml  
5% Stacking gel 
 30% acrylamide mix- 1.3 ml  
 M Tris (pH 6.8)- 1.0 ml  
 10% ammonium persulphate- 0.08 ml  
 10% SDS- 0.08 ml  
 TEMED- 0.008 ml  
 Water- 5.5 ml  
6x SDS gel loading buffer 
 Tris Cl (pH 6.8) 50mM  
 SDS 2%  
 Bromophenol blue 0.1%  
 Dithiothreitol 10mM  
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 Glycerol 10%  
10X Tris buffered saline (TBS) 
 NaCl- 80 g  
 Tris base- 24.2g  
Volume made to 1 liter with distilled water  
pH adjusted to 7.6 with 4N HCl 
1X Tris buffered saline tween (TBST) 
 10X TBS- 100ml  
 ddH2O- 900 ml  


















 The protein samples (40μg protein each) were denatured by heating at 
a temperature of 95ºC fora duration of 5mins along with the 6X loading dye. 
The proteins were seperated on a 10% SDS-PAGE gel which was then 
electroblotted onto a polyvinylidenedifluoride (PVDF) membrane (BioRad, 
USA). 5% non-fat milk powder was used to block the membranes in TBST for 
duration of 1 hour at room temperature. The addition of the necessary primary 
antibodies that were diluted in TBST was done after the washing of the 
membranes with TBST fora duration of 10mins. The membranes were 
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the membranes were again washed with 1XTBST for 3 times for duration of 
10 mins each. Following this, Horseradish peroxidase conjugated secondary 
antibodies were added to the membranes. The membranes were again 
incubated on a shaker for duration of 1 hr at room temperature. After 
incubation, the membranes were again washed twice with TBST and one time 
with TBS prior to the addition of the chemiluminescence substrate. 
Visualization of the immunoreactive bands on X-ray sheets was performed 
and quantification was done using the Densitometer and Quantity One 
software (BioRad, USA).  
2.12 Cryosectioning 
 Retrieval of the mice brains that were stored at a temperature of -80°C 
and mounting of the same on chucks using the cryomounting medium was 
performed. Each brain was cut along its coronal sections at a thickness of 
20μm and these were mounted onto gelatin-coated slides for 
immunofluorescence and Nissl staining.  
2.12.1 Nissl staining (Cresyl-fast violet staining) 
2.12.1.1 Materials required 
 Cresyl Fast Violet stain  
2.12.1.2 Procedure 
 The slides were immersed in ethanol wherein the concentrations were 
in adecrimental series before finally immersing them in water. This was 
followed by immersion in cresyl-fast violet stain for a duration of twenty 
minutes before passing them through 70%, 95% and 100% ethanol and 
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ultimately in two washes of histoclear. Drying of the slides was done by 
mounting them with the help of Permount. A Nikon light microscope (Japan) 
was used in the visualization and imaging of the dopaminergic neurons.   
2.13 Immunofluorescence studies 
2.13.1 Materials required 
 Fluoroshield with DAPI (Sigma, USA)  
 PBS (10X) (BioRad, USA)  
 Paraformaldehyde (Sigma) – 4% prepared in 0.1M phosphate buffer 
(pH 7.4)  
 PBS containing 0.1% Triton-X 100 (PBS-TX)  
 0.05M Tris buffered saline (TBS; pH 7.6)  
 3,3’ diaminobenzidinetetrahydrochloride (DAB) solution  
Table.2 List the primary and secondary antibodies used. 
Primary antibodies 
 
Antibodies Source Commercial source Dilutions 
TH 
 
Rabbit Sigma Aldrich, 




Rabbit Santa Cruz, USA 1: 200 
Sphk1 Rabbit Santa Cruz, USA 1: 100 





2.13.2.1  Immunofluorescence in vivo 
 The cryosections were washed in 1X PBS three times for a duration of 
10 mins each. This was then followed by the endogenous peroxide activity 
being quenched in 0.3% hydrogen peroxide in methanol fora duration of 
20mins. The sections were rinsed in PBS thrice after which, they were 
incubated in the primary antibody targeted against TH at a temperature of 4°C 
overnight was done. This was followed the next day by the washing of the 
sections in PBS 3 times and Cy3 conjugated secondary antibody was added.  
Following this, the sections were again incubated at room temperature for a 
duration of 1 hr. This was followed by washing of the sections 3 times in PBS 
and then mounting them with a coverslip using a fluorescent mounting 
medium (Fluoroshield with DAPI, Sigma, USA). A confocal microscope 
(FV1000, Olympus, Japan) was used in the visualization of cellular 
localization.  
2.13.2.2 Double immunofluorescence labeling in vivo 
 The cryosections were stained as described in the previous section. 
However, the staining was performed with a small change of making use of a 
cocktail of primary antibodies against TH and Sphk2. The primary antibodies 
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 1: 100 
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were addedand the sections were incubated at4°C overnight.  On the next day, 
the sections were washed 3 times in PBS. This was then followed by 
incubating with the relevant FITC/CY3 conjugated secondary antibodies, fora 
duration of 1 hr at room temperature. The sections were again washed with 
PBS 3 times, after which the slides were mounted and visualized as described 
in the previous section 
2.13.2.3 Immunofluorescence in vitro 
 The medium was removed from the 24- well plates and the cells were 
washed with PBS 3 times and fixed with 4% paraformaldehyde fora duration 
of 20 minutes. This was followed by blocking of the cells using 5% goat 
serum for 1 hr after which the incubation of the cells was performed at a 
temperature of 4°C overnight with the primary antibody. On the next day, the 
cells were washed in PBS thrice after which the cells were incubated for an 
hour with the Cy3 conjugated secondary antibodies. After incubation the cells 
were again washed in PBS 3 times for duration of 10 mins each. Following 
this the cover slips were carefully removed from the wells and mounted on 
glass slides using a fluorescent mounting medium (Fluoroshield with DAPI, 
Sigma, USA). A confocal microscope (FV1000, Olympus, Japan) was used to 
visualize the cells 
2.13.2.4Double immunofluorescence labelling in vitro 
 The cells were stained as described in the previous section. However, 
the staining was performed with a small change by making use of a cocktail of 
primary antibodies against TH and Sphk2. The primary antibodies were 
incubated at room temperature overnight. On the next day, the sections were 
washed 3 times in PBS. This was then followed by incubating with the 
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corresponding FITC/CY3 conjugated secondary antibodies, fora duration of 1 
hr at room temperature. The cells were again washed with PBS 3 times, after 
which the coverslips were mounted on to the glass slides and visualized as 
described in the previous section. 
2.14 Localization studies using mitotracker dye 
2.14.1 Materials required 
 Mitotracker dye 
 DMSO 
 1XPBS 
 The primary and secondary antibodies for staining sphk2 
2.14.2 Procedure 
 The stock solution was prepared by diluting the lyophilized 
mitotracker dye in DMSO to a final concentration of 1 mM and was alliquoted 
into small tubes. The tubes were stored at -20OC away from light. For staining, 
the 1mM stock solution was further diluted to a working concentration of 
200nM in growth medium.  The cells were grown on coverslips coated with 
poly-l-lysine in 24 well plates. Before staining, the culture medium was 
removed from the wells and the cells were washed with warm 1XPBS for 2 
times. Following this, the culture medium containing mitotracker dye was 
added to the wells. The plate was then incubated at 37º C with 5% CO2 fora 
duration of 30 mins. The stained cells were then washed with warm 1XPBS 
for 2 times and were fixed using 4% PF. After fixing, the cells were then 
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washed with 1XPBS several times and stained with Sphk2 primary and 
secondary antibodies as mentioned in the previous sections. 
2.15 S1P ELISA 
2.15.1 Materials required 
 Sphingosine 1 Phosphate Assay Kit (Echelon Biosciences, USA) 
 ELISA plate reader 
 DI water 
2.15.2 Procedure 
 The concentration of intracellular S1P present in the MPP+-treated and 
in the Sphk2 knock down groups was estimated using the Sphingosine-1-
Phosphate Assay Kit (Echelon Biosciences, USA) following the 
manufacturer’s instructions. The reagents were prepared before the start of the 
experiment. 4 tablets of PBS were dissolved in 800ml of DI water. Serial 
dilutions of S1P standard were done according to the manufacturer’s 
instructions. The anti-S1P antibody was diluted in diluents buffer and mixed 
well. 18μl of Streptavidin HRP was added to 13ml of blocking solution. The 
samples were diluted in the ratio of 1:10 in delipidized human sera. The 
samples and standards were combined with the anti-S1P antibody using a 
coloured mixing plate. The coated microtitre plate was blocked by adding 
150μl of block solution and incubated at room temperature for 1 hr. After 
incubation, the microtitre plate was washed 4 times by adding 300μl of PBS to 
each well every time. The PBS was removed by flicking the microtitre plate 
followed by blotting on a paper towel. The colored mixing plate was kept in a 
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shaker for 30 secs for though mixing. 100μl of the mixture from the mixing 
plate were transferred to each well of the microtitre plate. The microtitre plate 
was incubated at room temperature for1 hr. After incubation, the plate was 
washed with PBS for 4 times. Following this, 100μl of the diluted streptavidin 
HRP was added to the sample and standard wells including the blank and 
control wells. The microtitreplate was sealed and incubated at room 
temperature for 1 hr. Washing step was carried out after incubation. 100μl of 
TMB substrate were added to each well of the microtitreplate and incubated 
for 30 mins. Following incubation 50μl of H2SO4were added to each well of 
the microtitre plate in order to stop the reaction. The absorbance was measured 
at 450nm using the SpectraMaxM5 micro plate reader. The concentration of 
S1P in the different treatment groups was calculated using the standard graph 
generated. 
2.16 Knock down studies 
2.16.1 Materials required 
 Silencer select pre-designed Sphk2 siRNA constructs, (Ambion, CA, 
USA)  
 Negative control siRNA  (Ambion, CA, USA)  
 Opti-MEM® I Reduced Serum Media (Invitrogen, CA, USA)  




 5 μl of siRNA (from the 10μM stock) and 4μl of 
lipofectamineRNAiMaxtransfection reagent were mixed in 500μl of opti-
MEM medium in eppendorf tubes and incubated at 37ºC for 20mins.The 
differentiated MN9D cells grown in 6 well plates were washed twice with 1X 
PBS.The SiRNA-lipofectamine complex was added to the cells along with 
2ml of opti-MEM in each well (the final concentration of SiRNA was 20nM 
per well). The cells were then returned to the incubator and incubated at 37°C 
with 5% CO2. After incubating for 8 hours, the opti-MEM was removed and 
complete medium containing 10% FBS was added to the cells. The cells were 
harvested at 24 hrs after incubation for RNA isolation. In order to perform 
Western blot and other protein analysis, the cells were harvested after 48 hrs 
of incubation. 
2.17 ATP Assay 
2.17.1 Materials required 
 MilliQ water  
  96 well plate 
 Microcentrifuge 
  Pipettes and pipette tips 
  Fluorescent or colorimetric microplate reader:  
  Heat block or water bath 
  Vortex 
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  Ice 
 protease inhibitors 
2.17.2 Procedure 
 Before starting the experiment the reagents were thawed at room 
temperature and were diluted following the manufacturers protocol. ATP 
standard was reconstituted with 100µl of Milli-Q water to generate a 10mM 
ATP standard stock solution. The ATP converter was diluted with 220μl of 
assay buffer. Similarly the developer mix was also dissolved in 220μl of assay 
buffer. After treatment the cells were harvested from the 6 well plates by mild 
trypsinization. Around 106 cells were collected for each assay. The harvested 
cells were washed with cold PBS for 2 times and were re-suspended in 100µl 
of ATP assay buffer containing protease inhibitor. The cells were 
homogenized by pipetting up and down and centrifuged at 4°C for two 
minutes at 13,000 rpm in order to remove insoluble materials. The supernatant 
was collected and kept on ice. 10μl of ATP standard 10mM solution was 
mixed with with 90 µl of ddH2O to generate 100µl of 1mM ATP standard. 
The standard curve dilutions were prepared following the manufacturers 
protocol. A master mix containing ATP assay buffer, ATP probe, ATP 
converter and developer mix was prepared based on the number of samples. 
Around 50μl of ATP reaction mix was added to wells of the 96 wells plate. 
Following which 50μl of standard or sample was added to the corresponding 
wells. The mixture was then incubated at room temperature for 30 minutes in 
dark. Immediately after incubation the absorbance was measured at 570nm 
using the SpectraMaxM5 microplate reader (Molecular Devices). The standard 
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curve generated was used to quantify the concentration of total ATP present in 
the different treatment groups. 
2.18 Extracellular ROS assay  
 The amount of ROS liberated by the different treatment groups was 
estimated using the Oxiselectin vitro ROS/RNS assay kit (Cell Biolabs). The 
conditioned medium from the different treatment groups were utilized to 
measure the total amount of ROS/RNS liberated by different treatment groups. 
Around 50μl of the sample and 50μl DCF standard were added to a 96 well 
plate. Following this,addition of around 50μl of the catalyst was done to each 
well. The plate was then incubated at room temperaturefor 5 mins.  After 
incubation, 100 μl of DCFH was added to all the wells. The plate was 
againincubated for 45 mins in the dark at room temperature. The relative 
fluorescence of the samplesandstandards was read at 480 nm excitation/530 
nm emissions. This was done using the SpectraMaxM5 microplate reader 
(Molecular Devices). The standard curve that was obtained following the 
manufacturers instructions was used to calculate the concentration of total 
amount of ROS/RNS released by the different treatment groups. 
2.19 Cell viability assay  
2.19.1 Materials required 
 CellTiter 96® AQueous One SolutionCell Proliferation Assay kit 




 Before starting the experiment, the CellTiter 96® AQueous One 
SolutionCell Proliferation Assay kit was thawed at room temperature. Around 
20µl of CellTiter 96® AQueous One Solution reagent was added to the wells 
of the 96-well assay plate containing the different treatment groups in 100µl of 
culture medium. After adding the dye, the plate was incubated 37°C for 1 to 4 
hrs in a humidified, 5% CO2atmosphere. The absorbance was measured at 490 
nm using SpectraMaxM5 micro plate reader (Molecular Devices). The cell 
viability was represented as percentage of viable cells as compared to controls.  
2.20 Statistical analysis 
 Mean±Standard Error of Mean (SEM) was used to represent the data 
and Graph pad prism software (version 4) was used for all analysis. Using 
one-way ANOVA or student’s t-test the calculation of Statistical significance 
between groups was done and *p<0.05, **p<0.01, ***P<0.001 was used in 






















3.1 Nissl staining 
 Nissl staining has been used extensively to investigate the morphology 
and pathology of neural tissue. In the present study, the coronal midbrain 
sections were subjected to Nissl staining post MPTP treatment, in order to 
study the loss of dopaminergic neurons in the substantia nigra. There was a 
striking decrease in the number of dopaminergic neurons in the substantia 




















Fig 1.A. Photomicrograph shows the Nissl stained substantia nigra (SNc) of 
the mouse brain.  B. Photomicrograph shows the Nissl stained substantia nigra 
sections of the control animal. C. Photomicrograph shows the Nissl stained 
sections from the substantia nigraat day 7 post MPTP treatment.   
3.2 Tyrosine hydroxylase staining 
 Immunofluorescence studies were performed on the midbrain sections 
using anti-TH antibody in order to check for the pathological changes in the 
substantia nigra. There was a marked reduction in the TH positive 
dopaminergic neurons in the substantia nigra post MPTP treatment when 






Fig 2. A. Confocal image shows the dopaminergic neurons in the SNc marked 
by TH in the control. B. Confocal image shows the dopaminergic neurons in 
the SNc region marked by TH on day 7 post MPTP treatments. There is a 
visible decrease in the number of TH-stained neurons in the SNc post MPTP- 
treatment.  
3.3 Expression pattern of TH substantia nigra at different time points in 
the MPTP induced mouse model 
 Tyrosine hydroxylase (TH) is a rate limiting enzyme in the dopamine 
pathway. TH has been shown to be down regulated in clinical PD cases. In 
order to study the effects of MPTP on the expression pattern of TH in the 





reduction in the protein expression of TH in the substantia nigra on day1, day 
3 and day 7 post MPTP treatments when compared to the saline injected 










Fig 3.A. Western blot analysis shows the decrease in the protein expression of 
TH in the substantia nigra at day1, day 3 and day 7 post-MPTP treatments. B. 
shows their corresponding bar graphs showing significant changes in the fold 
change following MPTP treatment (given as mean ± SD). The experiment was 
repeated 3 times, and a representative blot is shown here. Significant 
differences in protein levels between MPTP and control groups are expressed 
as follows: ***p < 0.001. 
3.4 Expression pattern of DAT in the substantia nigra at different time 
points in the MPTP-induced mouse model 
 DAT is essential for the transport of dopamine from the synaptic cleft. 
DAT has been implicated in several dopamine related disorders. Similar to 
TH, DAT expression is also down regulated in clinical PD cases. Hence in 
order to check for the expression pattern of DAT in the substantia nigra of the 
MPTP-induced mouse model Western blot analysis was performed. It was 
observed that the expression pattern of DAT decreases significantly on day 3, 











Fig 4.A. Western blot analysis shows the decrease in the protein expression of 
DAT in the substantia nigra at day 3 and day 7 post-MPTP treatments. B. 
shows their corresponding bar graphs showing significant changes in the fold 
change following MPTP treatment (given as mean ± SD). The experiment was 
repeated 3 times, and a representative blot is shown here. Significant 
differences in protein levels between MPTP treated and control groups are 
expressed as follows: **p < 0.01. 
3.5 Expression pattern of proinflammatory cytokine TNFα in the 
substantia nigra region post MPTP treatment 
 Several studies have reported the increased levels of proinflammatory 
cytokines such as TNFα in the brains of clinical PD cases. Hence, in order to 
verify if inflammation has occurred in the brain of MPTP-induced mouse 
model, the expression pattern of TNFα in the SNc on day1, day3 and day 7 
post MPTP-treatment as compared to the saline-treated controls was analysed. 
The expression pattern of TNFα increased at day 1 and it peaked at day3. 














Fig 5.A. Western blot analysis shows the increase in the protein expression of 
TNFα in the substantia nigra on day1, day 3 and day 7 post-MPTP treatments. 
B. shows their corresponding bar graphs showing significant changes in terms 
of fold change following MPTP-treatment (given as mean ± SD). The 
experiment was repeated 3 times, and a representative blot is shown here. 
Significant differences in protein levels between MPTP and control groups are 
expressed as follows: *p < 0.05. 
 
3.6 Expression pattern of iNOS in the substantia nigra region post-MPTP 
treatment 
 Inducible nitric oxide synthase (iNOS) also plays a major role during 
neuroinflammation. The protein expression pattern of iNOS in the SNc on 
day1, day3, and day7 post MPTP-treatment as compared to saline-treated 






significantly higher on days 1 and 3 post MPTP-treatment. However, on day 7, 











Fig 6. A. Western blot analysis shows the increase in the protein expression of 
iNOS in the substantia nigra region at day1, day 3 post-MPTP treatment. B. 
Densitometric analyses show the increase in the protein expression of iNOS in 
the substantia nigra region at day1 and day 3 post-MPTPtreatment. The 
experiment was repeated 3 times, and a representative blot is shown here. 
Significant differences in protein levels between MPTP-treated and control 








3.7 MN9D - a dopaminergic neuronal cell line 
 The differentiated MN9D cells were used to generate the in vitro 
model of Parkinson’s disease. The differentiated cells had long processes. 
Immuno fluorescence staining using anti Neu-N antibody was done to confirm 
their neuronal state. Further staining with TH antibody was also done to 








Fig7.A. Photomicrograph shows image of differentiated MN9D cells.  B. 
Confocal images shows the differentiated MN9D cells stained with neuronal 
marker NeuN, C. Confocal images show differentiated MN9D cells stained 
with dopaminergic marker TH  
3.8 Expression of Sphk1 in the dopaminergic neurons present in the 
Substantia nigra of the mouse brain 
 The cells in the substantia nigra exhibited intense immune staining for 
Sphk1. However, the expression of Sphk1 was not very specific to the 
dopaminergic neurons as it was distributed in other cell types as well. The 
stained cells were identified to be dopaminergic neurons as they were positive 
for tyrosine hydroxylase (TH)(Fig.8).  
 
Fig 8.  Confocal image shows the expression of Sphk1 in dopaminergic 
neurons. The first panel represents the TH marker for the neurons(8.a). The 
second panel represents the expression of Sphk1 in them (8. b).  The last panel 
is the merged image showing their colocalization(8.c). Scale bars, 50µm. 
3.9 Expression of Sphk2 in the dopaminergic neurons present in the 
Substantia nigra 
 The cells in the substantia nigra exhibited intense immune staining for 
Sphk2. Unlike Sphk1, the expression of Sphk2 was very specific to the 
dopaminergic neurons as it was not distributed in other cell types. The stained 
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cells were identified to be dopaminergic neurons as they were positive for 
tyrosine hydroxylase (TH) (Fig.9). 
 
Fig 9. Confocal images showing the expression of Sphk2 labeled in green (9. 
b) and TH labeled in red (9.a) in the dopaminergic neurons in the substantia 
nigraof the adult mouse. Last panel (9.c) shows their colocalization. Scale 
bars, 50µm. 
3.10 Expression of Sphk2 in the MN9D cells 
 In order to check for the expression of Sphk2 in the MN9D cells, 
double immunoflourescence was performed using TH and Sphk2 antibodies. 
The MN9D cells exhibited intense immune staining for Sphk2. The stained 
cells were identified to be the dopaminergic neurons as they were positive for 









Fig 10. Confocal images show the expression of Sphk2 in the MN9D cells. 
Panel 1(10.a) shows TH labeled in red. Panel 2(10. b) shows Sphk2 labeled in 
green, and the last panel (10.c) shows their co-localization. Scale bars, 50µm. 
 
3.11 Expression pattern of Sphk2 in the substantia nigra of the MPTP-
induced mouse model of Parkinson’s disease 
 Double immune fluorescence showed that the expression of Sphk2 in 
the TH labeled dopaminergic neurons in the substantia nigra were markedly 
decreased on day 3 and day 7 in the MPTP-induced mouse model of 
Parkinson's disease when compared to their corresponding controls.  Some 
sections were incubated with isotype controls and they did not show any 
immunoreactivity confirming that the anibodies used were specific (data not 







Fig 11.A. Confocal images showing the decrease in the expression of Sphk2 in 
the substantia nigra of adult mouse brain 3 days post- MPTP treatment when 
compared to the corresponding saline treated controls.  The red shows the TH 
(11.A. a, 10 A. d) and the green shows the Sphk2 expression in them (11.A.b, 
10.A.e). (10.A.c, 10.A.f) show their co-localization. Fig 11. B. Confocal 
images showing the decrease in the expression of Sphk2 in the substantia nigra 
of adult mouse brain at 7 days post MPTP treatment when compared to the 
corresponding saline treated controls.  Red shows the expression of cy3 
labelled dopaminergic neurons (11.B.a, 11.B.d) and green shows the 
expression of Sphk2 in them (11.B.b, 11.B.e) and the last panel shows their 
colocalization(11.B. c, 11B.f).Scale bars, 50µm. C, D. Bar graphs show the 
decrease in the fluorescence intensity of Sphk2 in the MPTP-treated groups 
when compared to the saline injected controls.Significant differences in the 
intensity levels between MPTP-treated and control groups are expressed as 
follows: *p < 0.05; **P< 0.01 
3.12 Gene expression analysis and protein expression of Sphk2 in the SNc 
on day 1, day 3 and day 7 post-MPTP treatment. 
 The mRNA expression of Sphk2 was found to be significantly 
decreased in the SNc on day 1, day 3 and day 7 post MPTP-treatment when 
compared to the control mice. Western blot analysis also revealed that the 











Fig 12.Bar graphs in Ashow the mRNA expression of Sphk2 in the tissue 
samples from the substantia nigra of adult mouse brain on day 1, day 3, and 
day 7 post-MPTP treatments. Each bar is a graphical representation of the fold 
changes quantiﬁed by normalization to β-actin as an internal control. 
Differences in the mRNA levels are signiﬁcant (***P < 0.001, **P<0.01) 
when compared to the controls. B. Western blot shows the protein expression 
Sphk2 in the tissue samples from substantia nigra of adult mouse brain on day 
1, day 3 and day 7 post-MPTP treatments. C.Corresponding bar graph 
showing significant changes in the fold change following MPTP-treatment 
(given as mean ± SD). The experiment was repeated 3 times, and a 
representative blot is shown here. Significant differences in protein levels 
between MPTP-treated and control groups are expressed as follows:**p < 
0.01.  
3.13 The expression pattern of Sphk2 decreased significantly in MN9D 
cells treated with MPP+ 
 The expression pattern of Sphk2 was examined 
immunohistochemically in the MPP+-treated MN9D cells. Double 
immunoflourescence revealed that the expression of Sphk2 in the TH labeled 
MN9D cells markedly decreased at different time points ranging from 6hrs, 
12hrs, 24hrs post-MPP+ treatment, when compared to their corresponding 





Fig 13. Confocal images show the decrease in the expression of Sphk2 in the 
MN9D cells at 6hrs, 12hrs and 24hrs post MPP-treatment when compared to 
the control groups.  Red labelling shows the expression of TH labelled 
dopaminergic neurons (a,d,g,j) and green labelling shows the expression of 








3.14 mRNA expression and protein expression of Sphk2 in the MN9D 
cells at 6hrs, 12hrs and 24hrs post MPP+- treatment. 
 The mRNA expression of Sphk2 significantly decreased at different 
time intervals extending from 6 hrs to 24hrs in the MN9D cells treated with 
MPP+ when compared to that of the controls.Similar results were observed in 
the Western blot analysis. The protein expression of Sphk2 also showed a 
significant decrease in the MN9D cells at 6hrs, 12hrs and 24hrs post-MPP+ 
treatment. The present results thus indicate that MPP+ decreased the 













Fig 14.A. Bar graphs show the mRNA expression of Sphk2 in the MN9D cells 
at 6hrs, 12hrs, and 24hrs post MPP +-treatment. Each bar is a graphical 
representation of the fold changes quantiﬁed by normalization to β-actin as an 
internal control. Differences in the mRNA levels are signiﬁcant (**P < 0.01, 
***P<0.001) when compared to the controls. B. Western blot shows the 
decrease in the protein expression of Sphk2   in the MN9D cells at 6hrs, 12hrs, 
and 24hrs post-MPP+ treatment. C.Histogram showing significant changes in 
the fold change following MPP+ treatment (given as mean ± SD). The 
experiment was repeated three times, and a representative blot is shown here. 
Significant differences in protein levels between MPP+ and control groups are 
expressed as follows: **p < 0.01. 
3.15 Localization of Sphk2 in the MN9D cells. 
 Western blot analysis was performed in order to check for the 
localization of Sphk2 in the MN9D cells. Different subcellular fractions were 
analysed for the presence of Sphk2. It was observed that Sphk2 was 




band was detected in the cytosolic fraction. This result was further confirmed 
by immunoflourescence, using mitotracker. There was a very strong 
colocalization of Sphk2 in the mitochondria stained with the mitotracker dye, 







Fig 15.A. Western blot shows the protein expression of Sphk2 in the 
mitochondrial fractions in the MN9D cells. B. Confocal images show the 
localization of Sphk2 in the mitochondria in the MN9D cells. Red labelling 
shows the mitotracker staining in the MN9D cells and green labelling shows 
the expression of Sphk2 and the last panel shows their colocalization. Scale 
bars, 50µm 
3.16 Decrease in the expression levels of PGC-1α in the substantia nigra 
post MPTP- treatment 
 PGC-1α has evolved as a key gene regulating mitochondrial 
functioning. Down regulation of PGC-1α has been reported in several clinical 






substantia nigra of the MPTP-induced mouse model, Western blot analysis 
was performed. There was a significant reduction in the protein expression of 
PGC-1α in the substantia nigra region on day 1, day3 and day7 post MPTP 




















Fig 16.A. Western blot shows the protein expression PGC-1α in the tissue 
samples from substantia nigra of adult mouse brain at day 1, day 3 and day 7 
post-MPTP treatment. B. shows their corresponding bar graphs indicating 
significant changes in the fold change following MPTP treatment (given as 
mean ± SD). The experiment was repeated 3 times, and a representative blot is 
shown here. Significant differences in protein levels between MPTP-treated 
groups and the control groups are expressed as follows: ***p < 0.001. 
3.17 Decrease in the expression levels  of  NRF-1 in the substantia nigra 
post-MPTP treatment 
 PGC-1α functions through its downstream target NRF-1.  Hence, in 
order to evaluate if NRF-1 was altered in the MPTP-induced mouse 
model,Western blot analysis was performed. There was a significant decrease 
in the protein expression of NRF-1 in the substantia nigra on day 1, day3, and 














Fig 17.A. Western blot shows the protein expressionof NRF-1 in the tissue 
samples from the substantia nigra of adult mouse brain on day 1, day 3 and 
day 7 post-MPTP treatments. B. shows their corresponding bar graphs 
showing significant changes in the fold change following MPTP treatment 
(given as mean ± SD). The experiment was repeated 3 times, and a 
representative blot is shown here. Significant differences in protein levels 
between MPTP treated groups and the control groups are expressed as 
follows: *p < 0.05; **p < 0.01. 
3.18 SiRNA mediated knockdown of Sphk2 in the MN9D cells. 
 Gene knockdown of Sphk2 was performed in MN9D cells using three 
different siRNA constructs (S1, S2). Transfection of siRNA construct S3 
significantly decreased the endogenous mRNA levels of Sphk2 by almost 84% 
in MN9D cells after 24h of transfection in comparison to the cells transfected 
with negative control siRNA. Western blot analysis also showed a significant 















Fig 18.A. Bar graph showing the significant decrease in the mRNA expression 
of Sphk2   in the MN9D cell line after tranfecting the cells with 3 different 
siRNA constructs targeting Sphk2. Each bar is a graphical representation of 
the fold changes quantiﬁed by normalization to β-actin as an internal control. 
About 84% reduction in the gene expression was achieved using construct 2. 
Differences in the mRNA levels are signiﬁcant (*P < 0.05) when compared 
with negative controls. B. Western blot showing the protein expression of 
Sphk2   in the MN9D cells transfected with siRNA targeting sphk2. C. Bar 
graphs show the significant changes in terms of fold change following 
transfection (given as mean ± SD). The experiment was repeated 3 times, and 
a representative blot is shown here. Significant differences in protein levels 
between the siRNA transfected groups and the negative control groups are 
expressed as follows: **p < 0.01. 
3.19 Knockdown of Sphk2 reduces intracellular level of S1P 
 In order to investigate whether the loss of function of Sphk2 has any 





observed that the knockdown of Sphk2 led to a significant reduction in the 
intracellular levels of S1P when compared to that of the control groups. A 








Fig 19.Bar graph showing the decrease in the concentration of S1P in the 
MN9D cells at 24hrs post-MPP+ treatment and in the siRNA-transfected 
groups(given as mean ± SD). The decrease in the concentration was 
significant (**P < 0.01). 
 
3.20 Effect of S1P treatment on phosphorylated CREB 
 S1P has been shown to be able to activate phosphorylated CREB. In 
order to verify if S1P is able to activate phosphorylated CREB in the MPP+-
treated groups Western blot analysis was performed. There was a significant 
increase in the levels of p-CREB in the S1P-treated groups and in the MPP+- 
treated groups which were treated with exogenous S1P.  However, the levels 





























Fig 20.A. Western blot shows the protein expression of total CREB, p-CREB 
and β-actin in the MN9D cells following treatment with S1P.B, C. Bar graphs 
showing the significant changes in terms of fold change (given as mean ± SD). 
The experiment was repeated 3 times, and a representative blot is shown here. 
Significant differences in protein levels are expressed as follows: **p < 0.01. 
3.21 Sphk2 knock down leads to the decrease in the expression of PGC-1α 
and its down steam targets 
 Previous reports have shown that activation of CREB leads to the 
activation of the major mitochondrial gene PGC-1α. Since S1P has an effect 
on CREB activation the present author sought to evaluate if knockdown of 
Sphk2 leads to changes in the expression of PGC-1α and its downstream 
targets. siRNA-mediated knock down of Sphk2 in the MN9D cells led to a 
significant decrease in the mRNA expression of PGC-1α along with its 














Fig 21.A, B and C Bar graphs show the significant decrease in the mRNA 
expression of PGC-1α, NRF-1 and TFAM in the MN9D cell line after 
transfecting the cells with siRNA targeting Sphk2. Each bar is a graphical 
representation of the fold changes quantiﬁed by normalization to β-actin as an 
internal control. Differences in the mRNA levels are statistically signiﬁcant 
(***P < 0.001) when compared with negative controls (n = 3) 
3.22 S1P increases the expression of PGC-1α and NRF-1 in the MPP+- 
treated MN9D cells 
 The ability of S1P to activate p-CREB in the MPP+ treated groups lead 
the present author to speculate that it might as well affect the expression of 
PGC-1α and its targets. Hence, the protein expressions of PGC-1α and NRF-1 
in various treatment groups were evaluated. It was observed that the 
expression of PGC-1α and NRF-1 increased significantly in the MPP+- treated 
groups which were treated with exogenous S1P. Interestingly it was observed 
that the increase in the protein levels of PGC-1α and NRF1 in the MPP+- 
treated groups (which were treated with exogenous S1P) was slightly more 




















Fig 22.A. Western blot shows the increase in protein expressions of PGC-1α, 
NRF-1 in the MN9D cells following treatment with S1P.B, C. Bar graphs 
show the significant changes in terms of fold change (given as mean ± SD). 
The experiment was repeated 3 times, and a representative blot is shown here. 
Significant differences in protein levels are expressed as follows: *p<0.05, 
**p < 0.01. 
3.23 Expression pattern of SOD 2 in the MPP+-treated groups and in the 
Sphk2 knock down group 
 Since the major genes involved in mitochondrial functions are affected 
in the MPP+-treated groups and in the Sphk2 knock down groups, the present 
 B 
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author sought to evaluate the gene expression pattern of SOD 2 in both groups. 
There was a significant reduction in the mRNA expression mitochondrial 
antioxidant gene SOD 2 in the MPP+-treated groups at different time intervals 
ranging from 6hrs, 12hrs and 24hrs. A similar decrease in the expression of 
SOD 2 was observed in the Sphk2 knock down group (Fig 23). 
 
 
Fig 23.A. Bar graphs show the significant decrease in the mRNA expression 
of SOD 2 in the MN9D cell line treated with MPP+. B. Bar graphs show the 
significant decrease in the mRNA expression of SOD 2 in the MN9D cell line 
after transfecting the cells with siRNA targeting Sphk2. Each bar is a 
graphical representation ofthe fold changes quantiﬁed by normalization to β-
actin as an internal control. Differences in the mRNA levels are signiﬁcant 
(***P < 0.001) when compared with negative controls (n = 3) 
3.24 Sphk2 knock down leads to the upregulation of ROS 
 A significant increase in the levels of ROS in the MPP+-treated groups 
and in the Sphk2 knock down groups when compared to the control groups 
was observed. However, the level of ROS was considerably less in the MPP+- 











Fig 24.Bar graphs show the ROS production in the MN9D cells in the various 
treatment groups when compared to the controls. Each bar is a graphical 
representation of the fold changes quantiﬁed by comparing the fluorescence 
values of the control and the treatment groups. Differences in the expression 
levels are signiﬁcant represented by *** p< 0.001 (n = 3) 
3.25 Level of total cellular ATP in the different treatment groups 
 Knockdown of Sphk2 also lead to a significant decrease in the levels of 
total cellular ATP in the MN9D cells which was comparable with the MPP+-
treated groups. However, the level of total cellular ATP was unaffected in the 











Fig 25.Bar graph shows the relative ATP levels in different treatment groups 
(Control, MPP, siSphk2, S1P, S1P+MPP) in the MN9D cells. Each bar is a 
graphical representation of the fold changes quantiﬁed by comparing the 
absorbance values of the control and the treatment groups. Differences in the 
expression levels arestatistically signiﬁcant and are represented by *p<0.05, 
** p< 0.01 (n = 3) 
3.26 Gene expression analysis of S1P receptors in the Substantia nigra of 
MPTP- induced mouse model of Parkinson’s disease 
 S1P exerts its function through binding to five G-protein coupled 
recptors(GPCRS) designated S1P1-5.  In order to evaluate which one of the 
receptors is involved in the protective effect of S1P, the mRNA expression 
pattern of all the five S1P receptors were analyzed using RT-PCR analysis at 
different time points post MPTP treatment. It was observed that the expression 
of S1P1 receptor significantly decreased at day1, day3, and day7 post-
MPTPtreatment.  Although there were some changes in the expressions of the 
































Fig 26.A Bar graphs show the significant decrease in the mRNA expression of 
S1P1 receptor in the substantia nigra on day 1 day 3 and day 7 post-MPTP 
treatment.B, C, D and E bar graphs show the changes in the mRNA 
expression of   S1P2 – P5 receptors in the substantia nigra region post MPTP-
treatment. Each bar is a graphical representation of the fold changes quantiﬁed 
by normalization to β-actin as an internal control. Differences in the mRNA 
levels are statistically signiﬁcant and are expressed as **P < 0.05, ***p 
<0.001 when compared to the controls (n = 3) 
3.27 Expression pattern of S1P1 receptor in the dopaminergic neurons    
of the substantia nigra 
      The cells in the substantia nigra exhibited intense immune staining for 
S1P1 receptor in them. The stained cells were identified to be dopaminergic 
neurons as they were positive for tyrosine hydroxylase (TH) (Fig.27).  
.    
Fig 27.Confocal image shows the expression of Sphk1 in dopaminergic 
neurons. The red staining represents the TH (27.a) marker for the neurons. 
The green staining represents the expression of S1P1 in them (27.b).The last 










3.28S1P1 receptor antagonist leads to the decrease in the expression 
pattern of PGC-1α  and NRF-1 in the MPP+-treated groups which were 
treated with exogenous S1P 
The protein expression pattern of PGC-1α and NRF-1 significantly decreased 







Fig28 A.Western blot shows the decrease in protein expression of PGC-1α 
and NRF-1 in the MN9D cells following treatment with W123.B, C. Bar 
graphs show the significant changes in terms of fold change (given as mean ± 
SD). The experiment was repeated 3 times, and a representative blot is shown 












3.29 S1P1 receptor antagonist leads to the activation of ROS in the MPP+- 
treated groups which were treated with exogenous S1P 
 In order to analyze, if S1P functions through S1P1 receptor, a 
commercially available antagonist for S1P1 receptor called W123 was used. 
Blocking of the receptor using the receptor antagonist resulted in the decrease 
in cell viability in the MPP+- treated groups which were pre-treated with S1P. 
Furthermore, there was also activation of ROS in the MN9D cells after 
blocking the receptor. However, there was minimal cell death in the MPP+- 






















Fig 29 A. Bar graph shows the increase in ROS activity in the MN9D cells in 
the control and the treatment groups. Each bar is a graphical representation of 
the fold changes quantiﬁed by comparing the flourescence values of the 
control and the treatment groups. Differences in the expression levels are 
statisticallysigniﬁcant (**P < 0.01) when compared with controls (n = 3). B. 
Bar graphs show the viability of the MN9D cells under different treatment 
conditions expressed as a percentage of the controls. Statistical significance is 
























 Parkinson’s disease (PD) is a progressive neurodegenerative disorder 
which is highly prevelant among aged individuals. The complications 
associated with the disease reduce life expectancy of the patients. As the 
disease progresses, its social and economic impacts increase over time for the 
patient, family and the health care systems. A prominent characteristic of this 
disease is the selective degeneration of dopaminergic neurons in the substantia 
nigra of the midbrain. Many aetiological triggers have been connected to PD, 
which includes genetic mutations, environmental toxins, age, etc (Jankovic, 
2008).  Nevertheless, the exact mechanism that prompts cell death in PD still 
remains largely unknown.  Owing to this lack of knowledge, treatment options 
for PD have stayed obscure. In recent years, various animal models of PD 
have been developed in order to understand the molecular mechanisms that 
underlie the pathogenesis of PD. The most widely used experimental model of 
PD involves the use of the selective neurotoxin called 1-methyl-4-phenyl-1, 2, 
3, 6-tetrahydropyridine (MPTP) (Schober, 2004). The mode of degeneration 
that occurs subsequent to the administration of MPTP in animals has provided 
a deeper insight into the understanding of the molecular mechanisms 
underlying PD. This is because, MPTP induces pathological changes which 
are similar to that seen in clinical PD cases. Hence, we have used this model 
for our study. 
4.1 Pathological changes observed in the MPTP-induced mouse model of 
Parkinson’s disease 
 An acute MPTP-induced mouse model of Parkinson’s disease was 
established in the present study following the previously established protocol. 
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However, a slight modification in the dosage regimen was adapted in order to 
minimize the mortality rate in the animals. Nissl staining, which is the most 
commonly used nucleic acid staining method for nerve tissue sections was 
done in order to evaluate the loss of dopaminergic neurons in the substantia 
nigra (Gittins & Harrison, 2004). The degenerating neurons showed 
condensed cell bodies and were fewer in number in the substantia nigra on day 
7 post-MPTP treatment, when compared to the saline injected controls. 
Additionally, immunofluorescence studies were performed using TH antibody. 
A significant loss of TH-immunopositive neurons was observed in the 
substantia nigra on day 7 post-MPTP treatment. These pathological 
observations validated our animal model thereby indicating that MPTP-
induced PD-like characteristics are specific in the mouse model of PD that has 
been established  
4.2 Expression pattern of TH and DAT in the MPTP induced mouse 
model 
 In order to observe the molecular changes effected by MPTP in the 
mouse model, gene expression analyses of TH and DAT were performed. 
Tyrosine hydroxylase (TH) is the major rate limiting enzyme in the dopamine 
biosynthesis. Thus, it controls the production of dopamine in the SNc of the 
midbrain (Haavik& Toska, 1998). Alterations in the expression of tyrosine 
hydroxylase has been shown to lead to neurodegenerative disorders (Goodwill 
et al., 1997).  Hence, in order to evaluate the expression pattern of TH in the 
SNc of the MPTP-induced PD mouse model, Western blot analysis was 
performed. It was observed that the protein expression of TH significantly 
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decreased on day 1, day 3 and day 7 post-MPTP treatment when compared to 
the saline treated controls.  Furthermore, the expression pattern of dopamine 
transporter (DAT) was also analysed. DAT facilitates the removal of 
dopamine from the synaptic cleft and deposits it back into surrounding cells. 
Similar to TH, down regulation of DAT has been reported in clinical PD cases 
(Harrington et al., 1996). In accordance with this data, our Western blot 
analysis revealed that the protein expression of DAT was significantly reduced 
in the substantia nigra on day 1, day 3 and day 7 post MPTP treatment. These 
results confirm that MPTP is able to induce molecular changes similar to that 
reported in human PD cases. 
4.3 Proinflammatory cytokine TNFα was upregulated in the SNc of 
MPTP-treated mice 
 A successful animal model of PD should mimic at least a few of the 
classical pathological features of the human PD. Many studies have 
demonstrated the involvement of proinflammatory cytokines in mediating cell 
death in PD (McGeer & McGeer, 2004).  Increased expression of TNFα has 
been reported in several clinical PD cases (Mogi et al., 1994). Hence, the 
present author evaluated the expression pattern of TNFα in the SNc of the 
MPTP-induced mouse model of PD. The protein expression pattern of TNFα 
was found to be increased on day1, and it peaked on day 3. Nevertheless, the 





4.4 Expression pattern of iNOS in the SNc of MPTP-treated mice 
 Post-mortem brain samples from the SNc of clinical PD cases have 
revealed that the cells in the SNc express increased amount of iNOS(Levecque 
et al., 2003).  Increased iNOS expression has been shown to induce neuronal 
cell death in various animal models (Hunot et al., 1996)(Liberatore et al., 
1999b).  Furthermore, it has been reported that nitric oxide synthase is 
concentrated in the dopaminergic neuronal tract, and has been shown to 
interact with reactive intermediates of dopamine metabolism (Egberongbe et 
al., 1994).  Hence, in order to evaluate if iNOS is upregulated in the SNc of 
the MPTP-induced mouse model, Western blot analysis was performed. It was 
observed that the expression of iNOS significantly increased on day 1 and it 
peaked at day 3 post-MPTP treatment. However, after day 7, the iNOS was 
almost undetectable. These results clearly indicate that the iNOS is induced 
immediately after MPTP treatment. But, its expression gradually reduces as 
the degeneration progresses. 
4.5 In vitro model for PD - using MN9D cell line 
 The MN9D cells were treated with MPP+ in order to generate the in 
vitro model of PD. The MN9D cells belong to an immortalised cell line 
formed by the fusion of embryonic ventral mesencephalic and neuroblastoma 
cells. These cells have been widely used as a model of dopaminergic neurons 
as they express tyrosine hydroxylase, and synthesize and release dopamine 
(Choi et al., 1992). In the present study, the MN9D cells were stained using 
TH and Neu-N antibodies in order to confirm their dopaminergic and neuronal 
characters. It was observed that the MN9D cells exhibited intense staining for 
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both TH and Neu-N, indicating that they are dopaminergic neurons in nature. 
Furthermore, these cells developed extended processes like neurons when they 
were treated with sodium butyrate. 
4.6 Dopaminergic neurons of the substantia nigra expresses Sphk2 
substnatially when compared to the first isoform Sphk1 
 The relative levels of the sphingolipid metabolites are governed by two 
major enzymes namely Sphk1 and Sphk2. However, these enzymes have been 
shown to have opposing roles. Sphk1 has been shown to be anti-apoptotic 
while Sphk2 has always been a “bad kinase” triggering apoptosis (Neubauer & 
Pitson, 2013). A proper balance in the expression pattern of these enzymes is 
crucial for maintaining a balance in the sphingolipid rheostat. Owing to its 
protective nature, studies have always focused on the role of the first isofom 
Sphk1 in the brain.  Interestingly, in contrast to the usual reports on Sphk2 
being pro-apoptotic in nature, recent studies on animal models have created a 
few insights about SphK2 being a protective enzyme in neurological disorders 
(Pfeilschifter et al., 2011b). Nevertheless, the role of Sphk2/S1P signalling in 
the brain and especially in neurodegenerative disorder like PD remains 
elusive. On this note, the present study sought to study the role of Sphk2/S1P 
signalling in PD. In order to decipher this, the present author proceeded to 
check for the expression pattern of both the sphingosine kinases in the 
dopaminergic neurons of the substantia nigra under normal conditions. 
Immunofluorescence studies were performed using both Sphk1 and Sphk2 
antibodies. It was observed that the dopaminergic neurons of the substantia 
nigra exhibited immunostaining for both Sphk1 and Sphk2. However, it was 
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interesting to note that the expression of Sphk1 was not very specific to the 
dopaminergic neurons alone as it was stained in other cell types as well. In 
contrast, the expression of Sphk2 was very specific to the dopaminergic 
neurons of the substantia nigra. Moreover, the expression pattern of Sphk2 
was very high in the dopaminergic neurons, when compared to the expression 
pattern of Sphk1 in them. This result proves that Sphk2 is the major isoform in 
the dopaminergic neurons of the substantia nigra. This formed the basis to 
choose this particular isoform for the present study. 
4.7 Sphk2 is down regulated in the substantia nigra of the MPTP-induced 
mouse model of Parkinson’s disease and in the MPP+-treated MN9D 
cells 
 The intense staining and specific expression pattern of Sphk2 in the 
dopaminergic neurons of the substantia nigra led the present author to 
speculate that Sphk2 might have some important role to play in the 
dopaminergic neurons under pathological conditions like PD. Hence, the 
present author sought to evaluate the expression pattern of Sphk2 in the 
substantia nigra of the mid brain post-MPTP treatment in order to decipher the 
role of this isoform in MPTP-induced mouse model of PD. 
Immunofluorescence studies revealed that the expression pattern of Sphk2 in 
the substantia nigra region significantly decreased on day 3 and day 7 post- 
MPTP treatment. This result was interesting to note as some recent reports 
have mentioned that Sphk2 was upregulated in neurodegenerative disease (like 
Alzheimers disease). Gene expression study using RT-PCR analysis also 
showed that the expression of Sphk2 in the substantia nigra decreased 
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significantly on day 1, day 3, and day 7 post-MPTP treatment when compared 
to the controls. These results were further confirmed by Western blot analysis. 
Similar results were observed in the MPP+-treated MN9D cells, wherein the 
expression pattern of Sphk2 decreased significantly at different time intervals 
ranging from 6hrs to 24 hrs. These data are in accordance with the previous 
micro-array report from post-mortem brain samples from clinical PD cases 
where in it was reported that the expression of Sphk2 was significantly 
reduced in clinical PD cases (Simunovic et al., 2009). The above results 
indicate that Sphk2 might have some protective role in the dopaminergic 
neurons as they decreased upon treatment with MPTP. However, until now, 
there has not been a single report on its possible role in PD. Hence, in the 
present study, the author sought to evaluate the role of Sphk2 and its enigmatic 
multifaceted metabolite S1P’s role in PD.  
4.8 Localization of Sphk2 in the dopaminergic neurons 
 Localization of a particular protein is very crucial for its function in a 
particular type of cell. As discussed above, both isoforms of Sphk have 
different subcellular localization. In order to evaluate the role played by Sphk2 
in the dopaminergic neurons, the author sought to study the localization of 
Sphk2 in the MN9D cells. Various subcellular fractions (cytosolic and 
mitochondrial fractions) were immunoblotted using Sphk2 antibody. 
Interestingly, it was observed that Sphk2 protein with a molecular mass of 69 
kDa was detected only in the mitochondrial fractions and it was totally absent 
in the cytosolic fractions. Furthermore, immunofluorescence studies were 
performed using mitotracker dye and Sphk2 antibody in order to check if 
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Sphk2 colocalizes with the mitotracker. A very strong colocalization between 
the mitotracker and Sphk2 was observed, indicating that Sphk2 is localized in 
the mitochondria in the dopaminergic neurons, thereby suggesting a possible 
role in mitochondrial functions. This result is in accordance with a recent 
report showing that Sphk2 is present in the mitochondria in the murine 
cardiomyocytes (Strub et al., 2011).  Reports have shown that S1P’s 
localization is also in the mitochondria. The presence of Sphk2 and its 
metabolite S1P in the mitochondria suggests that Sphk2/S1P signalling axis 
might have some role in the mitochondria in the pathogensis of PD. This is 
important as mitochondrial dysfuntion has been reported as the major 
pathological event in PD.  
4.9 Down regulation of Sphk2 affects key genes involved in mitochondrial 
functioning 
 In order to study the role of Sphk2 in the dopaminergic neurons, 
functional studies were carried out in the MN9D cells. A previous study has 
indicated that Sphk2 is the major S1P-synthesizing isoform in normal rodent 
brain (Blondeau et al., 2007). In accordance with the above data, the present 
study demonstrated that the knockdown of Sphk2 in the MN9D cells led to a 
significant decrease in the levels of intracellular S1P.  Similar decrease in the 
intracellular levels of S1P was observed in the MPP+-treated groups. 
Mitochondrial dysfunction has been shown to be one of the primary causes of 
PD. Mitochondrial dysfunctions with complex 1 deficiency and impaired 
electron transport chain have been documented in clinical PD cases (Schapira, 
1993).  Mutations in proteins involved in mitochondrial functions have also 
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been reported in several familial PD cases (Bonifati et al., 2003). Furthermore, 
deletions in the mitochondrial DNA have also been reported in clinical PD 
cases (Bender et al., 2006b). Identification of the mechanisms promoting 
mitochondrial functions in neurons will help in developing new 
pharmacological approaches to prevent mitochondrial dysfunctions in PD. 
Mitochondrial functions and metabolism are regulated by numerous 
transcriptional networks. In recent years, the peroxisome proliferator-activated 
receptor c coactivator 1 (PGC1) family of transcriptional coactivators has 
emerged as the key regulators of mitochondrial metabolism. The PGC1 family 
comprises of three members, designated as PGC1α, PGC1β and the PGC 
related coactivator (PRC). These have been shown to interact with 
transcription factors and nuclear receptors to exert their biological functions 
(Handschin&Spiegelman, 2006).  Among the three members, PGC1α has been 
extensively studied by many research groups owing to its versatile function in 
regulating mitochondrial functions as it is localized in the mitochondria.  
PGC1α exerts its effect through its downstream target, nuclear respiratory 
factor 1 (NRF-1) (a transcriptional regulator) that acts on the genes encoding 
the subunits of the oxidative phosphorylation system. In addition to this, NRF-
1 also controls the expression of genes that are involved in replication of 
mtDNA (Lee & Wei, 2005). Down regulation of PGC1α has been reported in 
many neurodegenerative disorders. Reduced expression of PGC1α has been 
reported in Huntington’s disease (HD) (Chaturvedi et al., 2009). Ectopic 
expression of PGC1α in the striatum of transgenic HD mice has been shown to 
protect the neurons from neuronal atrophy (Cui et al., 2006). Down regulation 
of PGC1α has been reported in the post-mortem brains of Alzheimer’s disease 
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patients (Sheng et al., 2012).  Reports have shown that PGC1α plays a major 
protective role in PD. Down regulation of PGC1α target genes which are part 
of the respiratory chain have been reported in clinical PD cases (Zheng et al., 
2010).  Over expression of PGC1α has been shown to protect neuronal cell 
loss in the cellular model of PD (Wareski et al., 2009). Stereotactic injection 
of PGC1α along with PARIS in the substantia nigra can attenuate the neuronal 
loss caused by PARIS (Shin et al., 2011). Furthermore, PGC1α null mice are 
more sensitive to MPTP (St-Pierre et al., 2006). Consistent with these reports, 
the present results demonstrated that the expression of PGC-1α and NRF-1 
significantly decreased in the SNc of the mouse brain on day1, day 3 and day 
7 post-MPTP treatment. Furthermore, knockdown of Sphk2 significantly 
reduced both mRNA expressions and protein levels of PGC1α in the MN9D 
cells. The protein expression of NRF-1 which is the downstream target of 
PGC-1α also significantly decreased in the Sphk2 knock down group. A 
similar decrease was observed in the expression of TFAM (mitochondrial 
transcription factor A) which is also a down stream target of PGC-1 α. Various 
signal transduction pathways control the activation of PGC-1α, one of which 
is the cyclic adenosine monophosphate (cAMP) mediated signal transduction 
pathway. PGC-1α contains a functional CREB binding site that is required for 
cAMP activation (Herzig et al., 2001). Interestingly, it has been reported that, 
S1P has the ability to increase the production of cAMP, through the activation 
of adenylyl cyclase (AC). Moreover, CREB is activated upon treatment with 
S1P. In addition, some recent reports have shown that both S1P and PGC-1α 
are localized in the mitochondria (Aquilano et al., 2010; Strub et al., 2011). 
The effects of S1P on the activation of CREB led the present author to 
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hypothesize that S1P might promote mitochondrial functions through the 
activation of the pathway in the dopaminergic neurons in PD. In order to 
verify this hypothesis, the present author sought to study if S1P is able to 
activate CREB in the presence of the neurotoxin MPP+. Supporting this 
premise, the present results showed that the level of P-CREB was increased in 
the MPP+-treated groups which were treated with exogenous S1P. However, 
the levels of total CREB remained unchanged. The activation of p-CREB in 
the presence of the neurotoxin MPP+ suggest that S1P can have a simiar effect 
on PGC-1α and its down stream targets in the presence of the neurotoxin. 
Hence, the present author sought to study whether S1P can activate PGC1α 
and NRF1 in the presence of the neurotoxin MPP+. Supporting our hypothesis, 
the present study revealed that in the MPP+-treated groups which were treated 
with exogenous S1P, the expression levels of PGC-1α was unaffected and it 
was interesting to note that the expression pattern was slightly more than that 
of the control groups. However in the groups treated with MPP+ alone, the 
expression of PGC-1α was absent. Similarly, the expression of NRF-1 was 
unaffected in the MPP+- treated groups treated along with exogenous S1P.  
Various reports have shown that, PGC1α has the ability to detoxify ROS by 
stimulating numerous ROS scavenging enzymes (St-Pierre et al., 2006). These 
results demonstrate that S1P synthesized by Sphk2 in the mitochondria could 
possibly play a role to protect the neurons from MPP+-induced mitochondrial 




4.10 Knockdown of Sphk2 leads to the decrease in the expression of SOD2 
with a concomitant increase in the production of ROS 
 Although the primary function of mitochondria is to maintain cellular 
metabolism, they are also the main partaker in apoptosis. This is because they 
contain many proapoptotic proteins (i.e., cytochrome C which is released 
during programmed cell death).  Furthermore, they also generate reactive 
oxygen species (ROS) that can initiate apoptotic signaling. The connection 
between neurodegeneration and ROS has been well established (Beal, 2005). 
ROS are particularly active in the brain. This is because, the metabolism of 
neurotransmitters and excitatory amino acids serve as a factory for the 
production of free radicals. ROS in particular attack post-mitotic neurons, 
leading to neuronal damage and apoptotic cell death (Gilgun-Sherki et al., 
2001). Several studies on oxidative metabolism have revealed that PGC-1α 
maintains a “clean energy program” by increasing mitochondrial biogenesis 
along with the elevation in the cellular ROS-detoxifying capacity. Since the 
knock down of Sphk2 leads to a significant decrease in the expression pattern 
of PGC1α, the author hypothesized that the absence of Sphk2 might increase 
the level of ROS with an associated decrease in the ROS detoxifying enzyme.  
Hence, in the present study, the expression pattern of the ROS detoxifying 
enzyme SOD 2 was analyzed.  Supporting this hypothesis, it was observed that 
the PGC-1α target genes for the antioxidant enzyme, SOD2, showed a 
significantly lower expression in the Sphk2 knockdown groups when 
compared to that of the control groups. Since a decrease in the antioxidant 
enzyme SOD 2 has always been associated with the increase in the ROS, the 
levels of ROS generated by the various treatment groups were analysed.  It 
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was observed that the level of ROS generated was significantly higher in the 
MPP+-treated groups and in the Sphk2 knock down groups when compared to 
the control groups. 
4.11 Effects of treatment with extra cellular S1P on stress evoked by MPP 
+ in the MN9D cells 
 Previous report has shown that S1P has the ability to protect cells from 
apoptosis induced by H202 (Nakahara et al., 2012).  In accordance with this 
report, our results have shown that S1P has the ability to decrease the level of 
ROS in the MPP+-treated groups. Exogenous S1P (1 μM), protected the pool 
of neuronal cells against death and decreased the level of ROS in the cells 
treated with MPP+.  
4.12 S1P maintained the ATP levels in the cells treated with MPP+ 
It is a known fact that mitochondria is responsible for the production of ATP 
in the cell. Since Sphk2 and its metabolite seem to regulate the key genes 
involved in mitochondrial functioning, the author sought to study the 
expression pattern of ATP in the different treatment groups. Following 
knockdown of Sphk2, in the MN9D cells, there was a significant decrease in 
the levels of total cellular ATP which was similar to that observed in MPP+-
treated groups. However, the level of total cellular ATP was unaffected in the 
MPP+-treated groups in the presence of S1P. These findings imply that Sphk2 
is essential for normal functioning of mitochondria and its down-regulation 




4.13 S1P regulated pro-survival signalling by its specific receptor 
 In order to identify the receptor through which S1P exerts protection to 
mitochondria, the present author assessed the expression levels of all five S1P 
receptors (S1P1-5) in vivo. In the MPTP-induced PD mouse model, gene 
expression studies revealed that the expression of the S1P1 receptor was 
significantly decreased in the substantia nigra. Although the other receptors 
showed some changes they were not significant. 
4.14 Blockade of S1P1 receptor leads to the decrease in the expression 
pattern of PGC-1α and NRF-1 
 Further confirmation on the role of S1P1 receptor in preventing 
mitochondrial dysfunction was obtained from MN9D cells treated with MPP+ 
and W123, (a S1P1 receptor antagonist). In these cells, the expressions of 
PGC-1α and NRF-1 were down-regulated. These results show that blocking of 
S1P1 receptor prevents S1P from activating key genes involved in 
mitochondrial protection. 
4.15 Protective effect of S1P was abolished in the presence of receptor 
antagonist for S1P1 
 The levels of ROS in the culture medium from MPP++W123 treated 
MN9D cells were significantly higher when compare to MN9D cells treated 
with S1P alone. Moreover, the viability of the MN9D cells in the MPP+-
treated groups (which were treated with exogenous S1P), decreased in the 
presence of the receptor antagonist. From these findings, it could be inferred 
that S1P1 receptor is essential for S1P signalling and its subsequent protective 
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effects on mitochondria in dopaminergic neurons in PD. Our finding is in 
accordance with the demonstration by Pyszko and Strosznajder (2014) in 
human neurobalstoma cell line SH-SY5Y, wherein S1P was shown to 
specifically act via S1P1 receptor when subjected to treatment with 
MPP+.While their report was on the role of Sphk1 signalling, our data show 


































Parkinson’s disease (PD) is the most common and widelyspread 
neurodegenerative disorder after Alzheimer’s disease. PD is 
neuropathologically characterized by the degeneration of dopaminergic 
neurons in the SNc region. To date, the exact molecular mechanisms that 
underlie the pathogenesis of PD are unknown. Current and ongoing studies are 
giving deeper insights about the roles played by sphingolipids in regulating 
neuronal function. However, the roles played by these enigmatic lipid 
compounds in Parkinson’s disease are still unknown. The present study 
focuses on the role of Sphk2, one of the isoforms of sphingokinases, and its 
metabolite S1P in Parkinson’s disease. The MPTP-induced mouse model was 
used in the present study to examine the function of Sphk2/S1P signalling in 
the substantia nigra. Gene expression study and protein analysis revealed that 
the expression pattern of Sphk2 decreased significantly in the substantia nigra 
of the MPTP-induced mouse model of Parkinson’s disease. To date there has 
been no report about the localization of Sphk2 in the dopaminergic neurons.  
Western blot analysis using different subcellular fractions revealed that Sphk2 
was predominantly present in the mitochondria fraction, proposing for its 
possible role in the mitochondria. Mitochondrial dysfunction has been shown 
to play a major role in Parkinson’s disease. Hence, the present study focused 
on the role of Sphk2/S1P in mitochondrial functions. The present results 
demonstrated that S1P can activate p-CREB in the MPP+-treated MN9D cells. 
has a binding site for p-CREB.  The localization of Sphk2 in the mitochondria 
and the ability of S1P to activate p-CREB led to the hypothesis that the 
Sphk2/S1P signalling axis might be involved in controlling PGC-1α and its 
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downstream targets thereby controlling mitochondrial functions. In accordance 
with this hypothesis, functional studies using siRNA targeting Sphk2 in the 
MN9D cells revealed that the down regulation of Sphk2 alters the expression 
of PGC-1α and its downstream targets NRF-1 and TFAM. In addition, knock 
down of Sphk2 also significantly decreased the levels of intra cellular S1P. 
This result was comparable with the expression pattern of these genes in the 
substantia nigra of the MPTP-induced mouse model and in the MPP+-treated 
MN9D cells. However, addition of exogenous S1P significantly increased the 
expression pattern of PGC-1α and NRF-1 in the MPP+ treated MN9D cells. 
Knock down of Sphk2 led to a significant reduction in the expression of SOD2 
with an associated increase in ROS. In addition, the present data revealed that 
S1P has the ability to reduce the ROS concentration in MN9D cells treated 
with MPP+ with a concomitant increase the viability of a significant group of 
cells. There was also a significant decrease in the amount of total cellular ATP 
in the Sphk2 knock down groups and in the MPP+- treated groups. However, 
in the presence of exogenous S1P the levels of total cellular ATP was 
unaffected. Furthermore, gene expression analysis from the substantia nigra 
revealed that the mRNA expression of S1P1 receptor significantly decreased 
at different time point’s post-MPTP treatment. The present study also 
demonstrated that the S1P exerted its prosurvival effects through the S1P1 
receptors. Taken ogether these results show that Sphk2/S1P has an important 
role to play in the survival of the dopaminergic neurons thereby suggesting for 
its importance in the pathogenesis of PD. 
 . In summary, the present study has revealed the significance of Sphk2 
alteration in the pathogenesis of MPTP - induced PD mouse model. This 
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appears to be the first report to study the role of Sphk2/S1P signalling in the 
pathogenesis of PD. Nonetheless, the signalling mechanism through which 
S1P and PGC-1α offers protection to the mitochondria still remains unknown. 
In view of our findings it would be reasonable to state that Sphk2, S1P and 
their analogs could aid as prospective therapeutic targets in the treatment of 
PD. Future studies are necessary to untie the underlying mechanisms involved 
















5.1 Future Direction 
 To date, there has not been any report on the role of Sphk2 in PD. The 
present study demonstrates that Sphk2/S1P signalling plays a very important 
role in PD. To study the role of Sphk2 in vivo, specific inhibitors of Sphk2 can 
be injected into the brain of mice and the effects of the loss of Sphk2 on the 
dopaminergic neuronal survival and mitochondrial functions can be evaluated. 
Furthermore, exogenous S1P can be directly injected into the brain of MPTP- 
induced mice to examine if there is any improvement or increased survival of 
dopaminergic neurons in the SNc.However, whether S1P and PGC-1α are able 
to interact directly in mitochondria still remains an unsolved mystery. Future 
study has to be undertaken to understand the underlying mechanisms 
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